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ENGLISH SUMMARY 
A significant increase in the prostate cancer (PCa) incidence has made PCa 
a major health problem in recent years. Because of the often but 
unfortunately not always indolent nature of the disease, over-diagnosis and 
over-treatment are relevant clinical and ethical dilemmas.  
External beam radiotherapy (EBRT) is a well established treatment 
modality for PCa. Accuracy and precision are key words with regard to 
optimal survival and minimal toxicity and are fundamentals in modern 
radiotherapy (RT). 
Modern imaging has improved the ability to define RT target volumes. 
Especially treatment margins have been reduced through the use of more 
accurate treatment planning and image-guided technology.  
Increasing doses have lead to increased disease control. Aiming for minimal 
toxicity after radiotherapy, magnetic resonance imaging (MRI) delineation 
could be a possible tool, knowing that clinical target volumes (CTV) are up 
to 30% smaller after on MRI delineation compared to computer tomography 
(CT) delineation.  
The overall aim of the thesis was to explore the use of MRI target planning 
and a Nicle-Titanium prostate stent as fiducial marker for both MR-CT co-
registration and image guided radiotherapy (IGRT).  
Paper 1 evaluated toxicity 3 years after high-dose IGRT comparing target 
planning delineation on MRI and a prostate stent as fiducial with CT target 
planning and the use of gold markers as fiducials. The treatments were 
performed with the same radiation dose and planning target volume 
margins. A significantly smaller CTV was found in the MR-group. The 
CTV was correlated to a reduction in overall rectal toxicity, but not to a 
reduction in overall urinary toxicity. In general toxicity symptoms were few 
and mild. Significantly lower urinary frequency and urinary retention 
toxicity scores were observed following MRI delineation.  
Paper 2 looked into potential risk factors for rectal bleeding after RT. 
Different clinical and dosimetric factors were analyzed by univariate and 
multivariate logistic regression analyzes. The overall conclusion was that 
the CTV was the only robust risk factor augmenting the risk of rectal 
bleeding after RT.  
Five year survival and morbidity data was evaluated in paper 3, of the first 
patient cohort that underwent EBRT using MRI delineation and the prostate 
stent as fiducial. Overall survival, cancer specific survival and biochemical 
progression free survival were in accordance with recently published data.   
Late urinary and gastro-intestinal toxicity scores ≥grade 2 were also in 
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accordance with the lowest toxicity rates reported in recent literature using 
modern RT like IM-RT.  
Five year toxicity and quality of life (QoL) data were investigated in paper 4 
in two groups of patients using MRI or CT target delineation before PCa 
RT. The treatments were performed with the same radiation dose and 
planning target volume margins. Potential correlations with clinical and 
dosimetric parameters were also investigated.  
The mean CTV was 18% larger in the CT group compared to the MR group. 
Five year toxicities were in general few and mild; no grade 3 or 4 toxicity 
was found. No difference in overall urinary or rectal toxicity was found. No 
difference in global health was seen either.  The QoL bowel score were 
significantly lower in the MR group. 
The mean rectal dose and high rectal dose volumes were significantly 
smaller in the MR group. Rectal high dose was correlated to QoL bowel 
score and overall rectal toxicity. 
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DANSK RESUME 
En betydelig stigning i incidencen af prostata cancer tilfælde har gennem de 
seneste år sat fokus på prostata cancer behandlingen i Danmark. Prostata 
cancer er ofte, men langtfra altid en cancer sygdom med et fredeligt 
sygeforløb. Dette medfølger at overdiagnostisering og overbehandling 
bliver relevante kliniske og etiske problemstillinger. 
Ekstern strålebehandling (RT) er en gennemprøvet og effektiv behandling 
for prostata cancer. Præcision i forbindelse med strålebehandlingen er 
afgørende for bedst mulig overlevelse og minimale bivirkninger. Moderne 
scanningsteknikker har forbedret mulighederne for at definere og afgrænse 
målet (CTV) for stråleterapien. Øget stråledosis medfører bedre 
sygdomskontrol. 
Indtegning af prostata på MR scanning i stedet for på CT scanning kan være 
et skridt på vejen mod færre bivirkninger. Det er beskrevet i litteraturen, at 
indtegnede mål er op til 30 % mindre efter MR indtegning i forhold til CT 
indtegning.  
Målet med denne afhandling var overordnet at evaluere brugen af MR 
indtegning og en nikkel-titatium prostata stent som markør i forbindelse 
med MR-CT co-registrering ved billedvejledt strålebehandling (IGRT). 
Artikel 1 evaluerede bivirkninger 3 år efter højdosis IGRT og 
sammenlignede resultaterne efter prostata indtegning på MR og brugen af 
prostata stenten som markør sammen med indtegning på CT og brugen af 
standard guld markører. Patienterne blev behandlet med samme stråledosis 
og strålemarginer. CTV i MR gruppen var signifikant mindre end i CT 
gruppen. Der blev fundet en sammenhæng mellem CTV og reduktion af 
rektal toksicitet, men ingen korrelation til toksicitet fra urinvejene. Generelt 
var bivirkningerne få og milde. Der blev fundet mindre hyppig vandladning 
og urin retention i MR gruppen.  
Artikel 2 undersøgte potentielle risiko faktorer for rektal blødning efter 
strålebehandlingen. Forskellige kliniske og dosimetriske faktorer blev 
analyseret ved univariate og multivariate logistiske regressions analyser. 
Konklusionen blev samlet, at CTV var den eneste robuste risikofaktor for 
rektal blødning. 
Fem års evaluering af den første gruppe patienter der fik IGRT efter prostata 
indtegning på MR og med brug af prostata stenten som markør blev opgjort 
i artikel 3. Overlevelsen, den cancer specifikke overlevelse, biokemisk 
recidivfrihed og bivirkningerne var på niveau med nyeste publicerede data 
for moderne stråleterapi som f.eks. intensitets moduleret RT (IMRT).  
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I artikel 4 blev bivirkninger og livskvalitet 5 år efter strålebehandling for de 
2 grupper patienter, efter henholdsvis MR indtegning og CT indtegning, 
opgjort og sammenlignet. Mulige sammenhænge mellem kliniske og 
dosimetriske parametre blev også undersøgt. CTV var i gennemsnit 18 % 
større i CT gruppen i forhold til MR gruppen 
Generelt var bivirkningerne få og milde. Der var ingen forskel i urogenitale 
og gastrointestinale bivirkninger. Ingen forskel i livskvalitet overordnet. 
Den tarm-relaterede livskvalitet var signifikant bedre i MR gruppen. Der var 
signifikant mindre mean og høj stråledosis til rektum i MR gruppen. Høj 
dosis (v72Gy) var korreleret til den tarmrelaterede livskvalitet og til de 
samlede rektale bivirkninger.  
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ABBREVIATIONS 
 
3D-CRT: 3-dimensional conformal radiotherapy 
IG: image guided 
BPFS: biochemical progression free survival 
BT: brachytherapy 
ADL: activity of daily living 
BPFS: biochemical progression free survival 
CSS: cancer specific survival 
CT: computed tomography 
CTV: clinical target volume 
CTC-AE: common terminology criteria for adverse events 
Dmax: maximal dose in Gy to an organ or tumour target during RT 
Dmean: mean dose in Gy to an organ or tumour target during RT 
D2cc: minimal dose given to an area of 2cm³ of an organ or tumour target       
receiving the highest dose during RT 
EAU: European Association of Urology 
EBRT: external beam radiotherapy 
ED.: erectile dysfunction 
EORTC: European organisation for research and treatment of cancer  
GI: gastro-intestinal 
GTV: gross tumour volume 
Gy: gray   
HDR: high dose rate 
IGRT: image guided radiotherapy 
IMRT: intensity modulated radiotherapy 
Interm.: intermediate  
IPSS: international prostate symptom score 
LDR: low dose rate 
LRP: laparoscopic radical prostatectomy  
MR: magnetic resonance 
MRI: magnetic resonance imaging 
OS: overall survival 
PCa: prostate cancer 
PTV: planning target volume 
PSA: prostate specific antigen 
RRP: retropubic radical prostatectomy 
RTOG: radiation therapy oncology group 
RT: radiotherapy 
QoL: quality of life 
Vx: volume reciving minimum x Gy during RT 
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CHAPTER 1. INTRODUCTION 
Prostate Cancer (PCa) is today the most common malignant disease in men 
in Europe (excluding skin cancer). PCa is mainly diagnosed in men above 
the age of 50. PCa is a major health concern, particularly in the developed 
countries, because of their greater proportion of elderly men in the 
population. There has been a significant increase in the PCa incidence over 
recent years; this has mainly been attributed to the widespread use of 
prostate specific antigen (PSA) testing (1;2) and an increased consciousness 
about PCa in the developed countries in general. Since the PSA era PCa 
patients are now diagnosed without symptoms. This has also lead to a larger 
proportion of localized cancers among the newly diagnosed patients and 
consequently a larger proportion of these patients are potential candidates 
for curative treatments. However, a large proportion of the newly diagnosed 
PCa will turn out to be indolent tumours. PCa is known as a slowly growing 
cancer (most cancers develop over 10-20 years), it is a cancer that mainly 
affects older men, of which many will die of other causes and furthermore 
the PCa patients often have no symptoms from their cancer disease. Over-
diagnosis and over-treatment are therefore relevant clinical and ethic 
dilemma (3;4). Over-treatment is, in this case, defined as treatment of a 
disease that causes no threat to the man’s well-being during his lifetime (5). 
Today standard curative treatment for PCa involves surgery, brachytherapy 
and external beam radiotherapy (EBRT). Observational studies show that 
different treatment options all offer high rates of tumour control and nearly 
equal survival rates (6). However, these treatments can all be followed by a 
substantial number of side-effects. Consequently, both toxicity and Quality 
of Life (QoL) after treatment should be a major consideration in treatment 
decision making (7). 
With regard to radiotherapy (RT), modern imaging has improved the ability 
to define radiotherapy target volumes. Especially treatment margins have 
been reduced through the use of treatment planning and image-guided 
technology. Increasing doses have lead to increased disease control. 
Concurrently, technological advances may improve treatment related 
toxicity and potentially allow for further dose escalation (8).  
The purpose of this Ph.D was to explore a new treatment modality using 
magnetic resonance (MR) imaging  target planning and a  Nicle-Titanium 
(Ni-Ti) prostate stent as fiducial marker for both MR-CT co-registration and 
image guided radiotherapy (IGRT) focusing on the clinical outcome after 
radical prostate cancer radiotherapy. 
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CHAPTER 2. PROSTATE CANCER  
2.1. EPIDIMIOLOGY 
 
The incidence of prostate cancer increases with age, most frequently 
diagnosed in men above the age of 50. Over the past 10 years the PCa 
incidence almost doubled in Denmark; the incidence was 2288 in 2002 and 
4316 in 2012 (9). This increase has been explained by the widespread use of 
PSA as screening tool and an increased public awareness concerning PCa. 
The Danish PCa mortality rate though, is unchanged during the same 
period; 1149 in 2002 and 1187 in 2012. This is obviously followed by a 
dramatic increase in the prevalence; from 8.244 in 2002 to 28.944 in 2012 
(9). 
 
 
2.2. ETIOLOGY 
 
Only few risk factors for the development of clinical PCa have been 
identified. These include increasing age, ethnic origin and heredity. The 
frequency of autopsy-detected cancers seems to be almost the same in 
different parts of the world (10), this is to be seen in contrast to the 
incidence of clinical PCa that differs significantly between different areas; 
the incidence being high in Northern Europe and the USA. Interestingly, it 
has been shown that if Japanese men move from Japan to Hawaii, their risk 
of PCa increases, and it increases even further if they move to California, 
approaching the one of American men (11). These findings indicate that 
exogenous factors affect the risk of progression from latent PCa to clinical 
PCa. Infections/inflammatory, hormonal, dietary and lifestyle factors are 
thought to play a role in the development of PCa but no final 
recommendations have been made yet (12).  
 
2.3. DIAGNOSIS 
 
The opportunistic use of prostate specific antigen (PSA) has brought many 
asymptomatic patients to a urological service without symptoms. Possible 
presenting symptoms of PCa include lower urinary tract symptoms (e.g. 
urgency, frequency, nocturia, weak stream, incomplete bladder emptying 
and straining) and symptoms attributable to the local extension of the 
tumour (e.g. haematuria, pain, incontinence, loin pain due to ureteric 
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obstruction and impotence). In the relatively rare case of patients debuting 
with metastatic disease, symptoms like bone pain, anaemia and weight loss 
can be present. The diagnostic approach includes digital rectal examination 
(DRE), serum concentration of PSA and transrectal ultrasonography 
(TRUS). The definitive diagnosis is based on the histo-pathologic 
verification of adenocarcinoma in prostate biopsy cores or operative 
specimens.  
 
2.4. CLASSIFICATION AND CLINICAL STAGING 
 
The clinical staging of PCa is based on assessment of the primary tumour. 
PCa is staged as the biopsy-detectable but non-palpable localized tumour 
(T1), the tumour palpable at digital rectal examination (T2), the tumour with 
local spread e.g. dissemination through extra capsular extension and seminal 
vesicle invasion (T3) and the tumour that invades adjacent structures other 
than the seminal vesicles (T4).  
The current standard grading of adenocarcinomas of the prostate is the 
Gleason score (13). The Gleason score is the sum of the two most common 
patterns found on core biopsies or operative specimens. Since January 2009 
the worst grade has been incorporated in the Gleason score in needle 
biopsies even if comprising less than 5% of the cancer. Gleason scores 
considered as PCa range between 6 and 10, with 10 being the most 
aggressive. The natural history of the development of prostate cancer has 
been the subject in observational studies with patients with localized PCa. 
These studies show that the progression from localized cancer to PCa-
specific death may take more than 20 years, but obviously depends on 
clinical stage and Gleason score at diagnosis (14). Recognized prognostic 
factors are pre-treatment PSA, Gleason grading, number of biopsies with 
cancer and T-stage (15;16). Prostate cancer patients are classified into 3 
groups according to the D’Amico classification:  
 
Low risk: Intermediate risk: High risk: 
PSA<10ng/mL and 
clinical stage T1c-T2a 
and Gleason score <7 
PSA≥10 ng/mL, but 
<20ng/mL or clinical 
stage T2b-T2c or 
Gleason score =7. 
PSA ≥20 ng/mL or 
clinical stage >T2c or 
Gleason score >7. 
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CHAPTER 3. TREATMENTS OF 
LOCALIZED OR LOCALLY 
ADVANCED PROSTATE CANCER 
Albeit, the evidence from observational studies that many localized PCa 
tumours are biologically indolent, radical treatment of PCa is increasingly 
popular. This is despite the fact that mortality has not changed the past 10 
years and the lifetime risk of death from PCa is only 3% (17). Currently, 
clinical stage T1c represents 40-50% of new PCa cases (18). Data suggest 
that many men with localized PCa will not benefit from definitive treatment 
and that up to 45% of men with PSA detected PCa are candidates for 
conservative management; the “active surveillance” (19;20). Furthermore, if 
co-morbidities and a limited life expectance are present, treatment of more 
localized PCa may be deferred to avoid loss of QoL from the treatment. To 
some degree overtreatment of this patient group has probably been ongoing 
in Denmark for years. Patients with localized disease can today be treated 
with curative intent with surgery, radiotherapy or brachytherapy as the three 
recognized non-experimental treatments. To date there is no convincing 
evidence demonstrating survival superiority of any of these approaches to 
curative treatment for low and intermediate risk patients (21-24). 
Regardless, all treatments for localized PCa can cause bothersome 
complications, including urinary, sexual, and bowel dysfunction (6). 
Determining the need for treatment can be a complex decision and informed 
patients should make decisions after weighing the benefits and harms of the 
treatments. Further comparisons are warranted as techniques evolve across 
all therapies to continue to investigate any potential difference in outcome. 
High risk patients hold the greatest challenge and selection of therapy for 
these patients remains controversial (8). 
 
 
3.1. ACTIVE SURVEILLANCE (DEFERRED TREATMENT) 
Acknowledging the dilemma of being diagnosed with a cancer but not 
knowing if treatment is necessary and possibly being the subject to 
disabling side effects, deferred treatment – the “active surveillance” is being 
given more and more attention. Active surveillance aims at finding the 
proper timing of the intended curative treatment and thereby reducing 
overtreatment, rather than the delayed application of palliative treatment 
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options (18;19). Instead of treating the patient immediately after diagnosis, 
he remains under close surveillance using repeated DRE, PSA monitoring 
and repeated prostate biopsies. Today only data from non-mature 
randomized studies with follow-up of less than 10 years are available (24). 
Active surveillance is therefore only proposed to highly selected low-risk 
patients. 
3.2. SURGERY 
The most common radical treatment offered today is radical prostatectomy 
(RP). This involves removal of the entire prostate gland and resection of the 
seminal vesicles. With regard to intermediate and high-risk tumours the 
procedure is accompanied by bilateral pelvis lymph node dissection (24) In 
recent years robot-assisted laparoscopic prostatectomy is replacing the 
radical retropubic prostatectomy as golden standard in many centres 
particularly in Europe and the USA.  
The PIVOT study did not show a difference in survival at 10 years between 
watchful waiting and radical prostatectomy for PSA screen detected men 
with PSA of < 10ng/ml. There are two randomized clinical trials with long-
term follow-up that compared surgery to watchful waiting. These studies 
effectively reported conflicting results (25;26). The mortality of modern 
surgery is low (0,5%) (27), but incontinence and erectile dysfunction are 
common problems (28;29). Selected outcome data are presented in table I. 
Table I. Radical prostatectomy outcome data. 
Group Year Follow-
up 
Treatment Risk group BPFS 
(%) 
OS (%) CSS (%) 
Vassil (30)  2010 5 year RRP Interm. 60.2 - - 
Bill-
Axelson 
(26) 
2005 10 year - - 73 90.4 - 
Røder 
(31)  
2011 5 year RRP all 71.7 - - 
Merino 
(32) 
2013 5 year RRP/LRP all - 96.2 - 
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Mitsuzuka 
(33) 
2013 5 year RRP <70/≥70year 80.9/77.4 99.5/95.8 99.8/99.5 
 
 
3.3. BRACHYTHERAPY 
Brachytherapy (BT) is also known as internal radiation. It is based on the 
precise implantation of short-range radioactive seeds directly in the prostate 
to deliver radiation in the area requiring treatment. The irradiation only 
affects a localized area around the radiation source and exposure to 
radiation of healthy tissue farther away from the source is therefore reduced. 
The treatment is independent of positional changes since the radiation 
sources retain their correct position in relation to the tumour.  
Brachytherapy can be done as mono-therapy – either low-dose-rate (LDR) 
or high-dose-rate (HDR) – or in combination with EBRT (EBRT in 40-
50Gy dose combined with BT boost with either LDR or HDR) (34-36). 
LDR mono-therapy is carried out with permanent seed implantation in the 
prostate. Iodine-125 or Palladium-103 is the radioactive element of 
reference. The standard doses delivered are median 145 Gy for Iodine-125 
and median 125 Gy for Palladium-103(35;36). 
HDR brachytherapy as mono-therapy is a more recent treatment modality 
and seems to be associated with high biochemical control rates and low 
acute toxicity. Temporary needle catheters are placed in the prostate during 
the treatment, where high radiation dose is delivered over a short period. 
The radioactive source is usually iridium 192 or cobalt 60. Doses used in a 
limited number of studies published today are 26-38 Gy in 2-4 fractions (37-
42). Long-term follow-up data are not yet available and this treatment is not 
yet recommended outside formal studies (34).  
Combining BT and EBRT, the optimal dose of supplemental external EBRT 
is so far unclear (24). Likewise, no consensus concerning the optimal timing 
of each modality has been decided. BT can be given before EBRT, between 
EBRT fractions, or after completion of EBRT.  One randomised trail 
comparing EBRT alone with EBRT combined with HDR brachy showed a 
significant improvement in BPFS after the combined treatment compared to 
EBRT alone (34). There is no benefit from adding neoadjuvant or adjuvant 
ADT to brachytherapy. A significant correlation has been found between 
the implanted dose and recurrence rate (43). Selected outcome data are 
presented in table II and III.  
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Table II. LDR brachytherapy outcome data. 
 
Group Year Follow-
up 
Treatment Risk group BPFS 
(%) 
OS (%) CSS (%) 
Hinnen 
(44) 
2010 5 year I.125 perm - - - 79 
Jabbari 
(45) 
2012 5 year I-125 perm - - - 93 
Morris 
(46) 
2009 5 year I-125 perm low-interm 95.6 95.2 99.8 
Vassil 
(30) 
2010 5 year I-125 perm interm - - 89.5 
Zelefsky 
(47) 
2007 5 year I-125 perm low/interm 96/89 - - 
 
Table III. HDR brachytherapy outcome data. 
Group Year Follow-
up 
Treatment Risk group BPFS 
(%) 
OS (%) CSS (%) 
Barkati 
(48)  
2012 5 year 10-11.5 Gy 
×3 
low-interm 85.1 - - 
Demanes 
(37) 
2011 8 year 7Gy ×6 low-interm 97 95 99 
Rogers 
(40)  
2012 5 year 6.5Gy ×6 interm 94 98 100 
 
 
3.4. RADIOTHERAPY 
Radiotherapy has developed into the most important non-surgical treatment 
modality for cancer. It is a huge research area involving technology, biology 
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and physics. Definition, visualization and prediction of the target position 
are crucial components in any radiotherapy treatment. The development of 
CT, MR and cone-beam CT has made new technologies like conformal RT, 
intensity-modulated RT and image-guided RT possible. 
 
 
3.5. TARGET DEFINITION AND DOSE PRESCRIPTION 
The clinical target volume (CTV) is defined by the gross tumour volume 
(GTV) and the area of risk of microscopic spread. A margin is added to 
construct the planning target volume (PTV) to compensate for the predicted 
uncertainties in daily patient positioning, tumour movements and regions at 
high risk of extra prostatic extension (8;49).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagram to illustrate the main radiotherapy volumes. From the 
ICRU report 50.  
GTV: Gross tumour volume (detectable tumour volume).  
CTV: Clinical target volume (GTV plus volumes with expected subclinical                     
spread).  
PTV: Planning target volume (CTV plus safety margin for movements and 
deformation, technical uncertainties). 
TV: Treatment volume (receiving the prescribed dose). 
IV: Irradiated volume (exposed to significant doses with regard to normal 
tissue tolerance). 
 
 
In the matter of PCa the CTV is defined as the prostate gland. In the case of 
seminal vesicle invasion or risk of invasion (Partin tables) (50), the CTV is 
defined as the prostate gland plus the proximal third part of the seminal 
vesicles. Normally a margin of 5-15mm is added around the CTV to create 
the PTV (51;52), as illustrated in figure 2. 
GTV 
CTV 
PTV 
TV 
IV 
LONG-TERM FOLLOW-UP AFTER MODERN RADICAL PROSTATE CANCER RADIOTHERAPY 
24
 
 
 
 
Figure 2: MR slide of a prostate cancer patient. The PTV is generated from 
the CTV by a uniform expansion of 5 mm in all directions. 
 
Modern imaging has improved the ability to define radiotherapy target 
volumes. Computed tomography (CT) scans have been used as standard 
care in most centres for prostate definition, CTV delineation and RT 
treatment planning. However, limitations of CT include the inability to 
discriminate regions of disease within the prostate and challenges in 
differentiating prostate from surrounding fascia and musculature, especially 
at the apex. Thus, CT target delineation has been demonstrated to lead to an 
overestimation of the prostate volume Studies have described volume 
estimations up to 30% larger on CT compared to target delineation on 
magnetic resonance imaging (MRI)  e.g. the good soft-tissue visualization in 
magnetic resonance (53-55). CT-MR image fusion-based treatment planning 
allows more accurate prediction of the target volume (8;56). The CT-MR 
co-registration can be done in several ways; on bony landmarks, with 
endorectal coil or by intraprostatic fiducial markers. Additional precision 
may also be gained from fusion of other imaging technologies like 
ultrasound, magnetic resonance-spectroscopy and novel nuclear medicine 
images to standard CT (8). 
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Figure 3. Superior soft tissue differentiation is seen on MRI compared to 
CT. Left pictures: Prostate delineation on CT. Right pictures: Prostate 
delineation on MRI. 
 
3.6. DOSES AND FRACTIONS 
Different dose and fraction schedules have been used during the years in 
PCa RT. Several randomized studies have shown that dose escalation 
improves biochemical control but is also followed by an increase in toxicity 
(57-59). Before the application of 3-dimensional conformal radiotherapy 
(3D-CRT) radiotherapy doses were usually about 64 Gray (Gy) in 2Gy 
fractions. With better techniques several randomized studies have shown 
that dose escalation (range74-80Gy) has a significant impact on 5 years 
biochemical progression free survival rate. The meta-analysis of 
randomized, controlled trials from Viani from 2009 (60) provided 
convincing evidence that high-dose RT is superior to conventional dose RT 
in terms of preventing biochemical failure in low-, intermediate-, and high-
risk patients. They suggested that high-dose RT should be offered to all 
patients regardless their risk status. Some of the remaining questions are 
how high to escalate dose and what will the increased toxicity of dose 
escalation be in the era of IGRT. The actual recommendations from the 
European Association of Urology (EAU) guidelines working panel is a 
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minimum dose of 74Gy. Currently, standard treatment in most high volume 
centres consists of 75.6 to 81 Gy of radiation separated into 1.8-2 Gy 
fractions given daily during 7-9 weeks. The prolonged length of this 
standard prostate radiation coupled with advances in radiation therapy have 
stimulated interest in delivering more radiation per faction (consisting of 
fractions ˃ 2 Gy) for the purpose of reducing overall treatment time and 
thereby improving patient convenience and possibly reduce increasing 
health care costs. This type of shorter treatment regime using larger doses of 
radiation per fraction is called hypofractionation (5;61).  
Most tissue show a sparing effect of dose fractionation, so that the total 
doses for a given endpoint are higher if the dose is fractionated rather than 
when given as a single dose (62). Fractionated radiotherapy uses the 
differences in the DNA repair capacity of normal and tumour tissue. The 
alfa/beta ratio is a measure of the curvature of the cell survival curve and a 
measure of the sensitivity of a tissue to dose fractionation. It is also the dose 
at which the linear and quadratic components of cell killing are equal. 
In fast growing tissue including many tumours, cells have little time to 
repair photon induced DNA damage. The α/β ratio is then typically around 
10 Gy. In contrast, tissue with low renewal has a good opportunity for repair 
between fractions of irradiation. In such tissue, the α/β ratio is 3 Gy or 
lower. Slowly proliferating cells with low α/β ratio seems to be quite 
sensitive to an increased dose per fraction. PCa has an estimated α/β ratio of 
approximately 1.5 Gy, and hypofractioned regimes could be more efficient 
than conventional fractions of 1.8-2 Gy (63;64). Low α/β values (1.5 to 5 
Gy) have been observed for late responding normal tissues, and there are 
concerns about potentially increased late bowel and urinary toxicity 
following hypofractionation (65-67). 
3.7. TECHNICAL ASPECTS OF MODERN RADIOTHERAPY 
Since 10 years the development of two major technologies; the intensity 
modulated radiation therapy (IMRT) and the image-guided radiotherapy 
have not only improved survival but it has also reduced toxicity after 
prostate radiotherapy even after dose-escalations above 72Gy (51). 
3.7.1. IMAGE-GUIDED RADIOTHERAPY 
The development of IGRT in prostate RT was reinforced after 2 studies 
showed that rectum distension during target planning simulation was 
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followed by a reduction in biochemical survival (68;69). Variations in 
patient setup, rectal air, stool volume and bladder filling create prostate 
position uncertainties both daily and even under treatment (8). Daily 
prostate displacements more of 10-15mm have been described in patients 
(70;71). The limited ability to control for the location of a tumour 
compromises the accuracy with which radiation can be delivered to tumour-
bearing tissue. The following requirement for larger treatment volumes to 
accommodate target uncertainty restricts the radiation dose because more 
surrounding normal tissue is exposed. IGRT is based on repeated imaging 
during the course of radiotherapy. Out of multiple 2D images it is possible 
to construct a volumetric 3D image with soft tissue contrast. The created 
image is then registered to the planning CT this enables daily prostate 
position verification and patient setup correction. Using IGRT the treatment 
volumes can be optimized and tumouricidal doses can be delivered, 
achieving maximal tumour control with minimal complications. This 
reduction in setup uncertainties has been followed by a PTV margin 
reduction in many centres. Consequently several studies have reported about 
toxicity reduction obtained in several studies using modern EBRT (72;73). 
However, the today known IGRT technology does not eliminate the need 
for a margin. One study reports unexpected worse treatment outcome after 
the use of very narrow margins (74). There is still considerable scope for 
further improvement of IGRT systems. The ideal system would allow for 
precise daily imaging without significant extension of treatment time or 
patient exposure to additional radiation.  
 
 
3.7.2. INTRAPROSTATIC FIDUCIAL MARKERS 
Different types of gold markers with different length and diameter are used 
as standard intraprostatic fiducials markers. Minimum three gold markers 
are recommended to gain a triangulation that helps reposition the prostate in 
the three dimensions on 2D or 3D imaging. The use of the gold markers has 
increased both precision and accuracy of the EBRT but the markers also 
have some inconvenient. Positioning them is an invasive procedure with a 
non negligible risk of infection. They can migrate after their pose. The 
metallic artefacts they can create on the imaging may impair the 
visualisation of the contours of the prostate and impair correct delineation 
(51). Most commercialized gold markers today are not visible on T2 
weighted MRI; the images most suitable for prostate delineation. The RT 
treatment modality evaluated in this thesis is based on insertion of a 
commercial Ni-Ti prostate stent (MemokathTM) as marker (75-77). Ti has 
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the atomic number 22, and is easily seen on x-ray images, which makes it 
suitable for x-rays positioning. Ti has an electron density relative to water of 
3.7 and consequently good contrast is found using MV beam as well. The 
stent material is also non-magnetic and allows the use of the MR scanner on 
the patient with an inserted stent. The advantages compared to traditional 
gold markers are that the stent allows routinely co-registration of MRI and 
CT scans for treatment planning. It may be used for IGRT using both kV or 
MV or combinations. The size of the stent makes it a true 3D object, which 
allows calculations of both translation and rotation. The stent is removable 
using a flexible scope in an outpatient clinic setup. 
 
 
Figure 4. Three different stent designs have been investigated during the 
past years. To the left is the Memokath, which was developed for treatment 
of benign prostate hyperplasia. In the middle is the DS-I stent. To the right 
is the DS-II stent, which is used in the present studies. All three designs are 
made of Ni Ti memory shape metal.  
 
3.7.3. INTENSITY MODULATED RADIOTHERAPY 
Intensity modulated radiotherapy (IMRT) allows better dose distribution 
with step dose-gradients during RT. Using IMRT the radiation intensity 
across the fields of the applied beams is modularly; the beam is 
continuously adapted to the contour of the target volume by a multileaf 
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colliminator and thereby, regulate the radiation intensity during delivery. 
This allows improved target conformity and coverage and reduced dose and 
volume to the normal tissue. The risk of using IMRT and a highly 
conformal radiation field is geometrical misses because of the sharp edges 
between the radiation field and the surrounding tissue. With dose escalation 
organ movements become a critical issue using IMRT. The IMRT treatment 
must be accompanied by accurate image guidance in some form of IGRT. 
Otherwise it could result in both severe under dosage of the PTV or 
unacceptable high dose delivery to the normal tissue (78). As well as 
prostate motion during treatment imposes further technical challenges 
exacerbated by longer treatment times required for IMRT compared with 
four-field treatment. The EAU guidelines refer to IMRT with or without 
image-guided radiotherapy as the gold standard for EBRT for prostate 
cancer, even though far from all centres can offer it today. 
 
Figure 5. Examples of prostate cancer radiation fields with irradiation of the 
normal surrounding tissue.  
 
3.8. ADJUVANT HORMONAL THERAPY 
Androgen stimulation is mandatory for growth and survival of the PCa cells. 
Several randomized studies have established the indications for the 
combination of EBRT and androgen deprivation therapy (ADT) with regard 
to high–risk patients, as it increases overall survival (79-81). Whether this 
applies to all stages of prostate cancer is unclear. Some research suggests 
that ADT does not improve biochemical progression free survival in low 
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risk patients and intermediate risk-patients when adequate radiation doses 
are given. This is noted not only in patients treated with EBRT but also 
brachytherapy and surgery (82). Actual recommendations from the EAU 
guidelines are adjuvant hormonal therapy for a total duration of 3 years in 
patients with locally advanced disease. It must be mentioned though, that 
higher incidences of diabetes, cardiovascular disease, obesity and metabolic 
syndrome have been found in patients treated with long-term ADT (83). 
3.9. OUTCOME AFTER RADIOTHERAPY FOR PROSTATE 
CANCER 
EBRT technology has developed substantially the past decade, but so far no 
rapid impact on the mortality has been observed. The majority of PCa 
patients still die with their disease rather than of PCa,  this is due to  the 
advanced median age at diagnosis (70 years in Denmark in 2009 (84)) and 
prolonged natural history of early stage PCa.  The majority of studies 
reporting on the treatment outcome after EBRT for PCa use more soft 
endpoints as biochemical failure or clinical failure rather that cancer specific 
survival; these “surrogate endpoints” are used because patients rarely die of 
prostate cancer. Unfortunately, when using such surrogate endpoints, other 
factors not connected to therapy like the frequency of PSA measurements 
may have dramatic effect on reported outcomes, and it can be difficult to 
compare different study results (85). Clinically relevant outcome measures 
include overall survival (OS), cancer-specific survival (CSS), biochemically 
progression free survival (BPFS), toxicity and QoL. Selected outcome data 
are presented in table III and IV.  
Comparison of outcome data after EBRT for PCa must be done prudently 
because of the use of different treatment techniques, imaging, risk 
classification and patient characteristics. One recent reference study – the 
RTOG 9406 reported 5 year results of OS at 85%, CSS at 99% and BPFS at 
80% (86). 
 
Table IV. Radiotherapy outcome data. 
Group Year Follow-
up 
RT-
treatment 
Dose 
(Gy) 
Risk 
group 
BPFS 
(%) 
OS 
(%) 
CSS 
(%) 
Pervez 
(87) 
2014 5 years IMRT 86 high 91.7 86.7 - 
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Michalsky 
(86) 
2012 5 years 3D-CRT 78 low 80 88 - 
Wilcox 
(88) 
2014 5 years IG-IMRT 78 - 88 - 98 
Takeda 
(89) 
2012 5 years IG-IMRT 80 interm 100 100 100 
Takeda 
(89) 
2012 5 years IG-IMRT 80 high 82.2 91.7 100 
Vassil 
(30) 
2010 5 years - - interm 85.7 - - 
Merino 
(32) 
2013 5 years IMRT 76 all - 88.4 - 
Widmark 
(90) 
2009 10 years 3D-CRT 70 all 74.1 70.4 88.1 
 
Treatment related toxicity is, also in the matter of PCa, known as the dose-
limiting factor. Following the development in modern RT, toxicity levels 
have become very low. Data from recent studies are presented in table IV. A 
recent reference study from The Memorial Sloan-Kettering Cancer Center 
group has reported data on late toxicity from their experience in 1571 
patients with T1-T3 disease treated with either 3D-CRT or IMRT at doses 
of between 66Gy and 81Gy, with a median follow-up of 10 years. Both 
acute gastrointestinal and genitourinary toxicity appeared to be predictive 
for corresponding late toxicity. The overall rate at follow-up of CTC-AE 
grade 2 or more gastrointestinal toxicity was 5% with IMRT versus 13% 
with 3D-CRT. The incidence of grade 2 or higher late genitourinary toxicity 
was 20% in patients treated with 81Gy versus 12% in patients treated with 
lower doses. The overall incidences of grade 3 toxicity were 1% for 
gastrointestinal toxicity and 3% for genitourinary toxicity. The study 
underline that with dose escalation, genitourinary toxicity may become the 
predominant type of morbidity (91). A recent review on functional outcomes 
and complications from Budäus et al. from 2011 reported late 
gastrointestinal toxicity (RTOG scales ≥grade 2) from 3.1-29% and late 
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genitourinary toxicity (RTOG scales ≥grade 2 from 5.1-37% (92). Many 
factors are involved in the evaluation of toxicity and missing data on pre-
treatment function, natural deterioration in sexual function with age in this 
patient group and missing data on co-morbidity are important confounders. 
Sexual morbidity in less reported in the literature. RT affects erectile 
function to a lesser degree that surgery, according to a retrospective analysis 
(93). One meta-analysis found a chance of 0.55 to preserve erective function 
1 year after RT (94). Diabetes and ADT treatment have been reported as 
predictors for erective dysfunction (95). It is also known that LH-RH analog 
treatment can be followed by permanent sexual dysfunction (96).  
In general it must be said that toxicity is difficult to compare and broad 
variation between studies are often seen. The major explanation of this 
variation if often differences in study design (e.g. prospective or 
retrospective data collection, lack of baseline recordings), different scoring 
scales (RTOG, CTC-AE, LENT-SOMA) and different information sources 
(patient or physician assessed toxicity). Information about study design and 
the collection of data should be described in details, and comparisons 
between studies should be done with care. 
 
Table V. Selected toxicity outcomes after high dose RT. Recent studies 
using IGRT and/or IMRT. CTC-AE toxicity scores.  
Group Year Follow-
up 
RT-
treatment 
Dose 
(Gy) 
Risk 
Group 
Urinary 
≥grade2 
GI 
≥grade2  
ED 
≥grade2 
Pervez 
(87)  
2014 5 year IMRT 68 high 19.4% 2.4% - 
Wilcox 
(88)  
2014 5 year IG-IMRT 78 interm-
high 
2.1% 3.4% 9.1% 
Takeda 
(89)  
2012 5 year IMRT 76-80 interm-
high 
6.3% 6% - 
Zelefsky 
(97) 
2012 3 year IGRT 86.4 - 10.4% 1% - 
 
 
Tabel VI. Selected toxicity outcomes after high dose RT. RTOG toxicity 
scores. 
Group Year Follow-up RT-
Treatment 
Dose 
(Gy) 
Risk 
group 
GU 
≥grade2 
GI 
≥grade2 
Peeters 
(98)  
2005 3 year 3D-CRT 78 interm-
high 
30.2 26.5 
Pollack 
(99)  
2002 6 year CRT 78 all 10 26 
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Zietman 
(100)  
2010 5 year 3D-CRT 79.2 - 29 25 
Dearnaly 
(57) 
2007 5 year CRT 78 all - - 
Sutani 
(101)  
2015 3 year IMRT 78 all 6.8 7.9 
 
GU: genitourinary. GI: gastrointestinal. ED: erective dysfunction.  
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CHAPTER 4. ASPECTS OF 
RADIOBIOLOGY 
The damaging effect of radiation therapy arises from its ability to ionize 
molecules in cells. The DNA is the critical target for radiation induced cell 
killing. Ionizing radiation causes both direct damage on DNA and indirect 
damage by producing free radicals that causes further DNA-damage. The 
cells die either an early cell death caused by the initial cellular damage or in 
the case of the majority of cells; a late cell death a relatively long time after 
irradiation; after failed attempts of cell proliferation (mitotic catastrophe). 
The risk of radiation-associated injury of normal tissue is dependent of 
many factors like the volume of normal tissue irradiated, the total radiation 
dose delivered and the number of fractions delivered (dose per fraction). 
Pre- existing medical conditions and probably also genetics influence the 
risk of normal tissue damage too. The organs inherent sensitivity to 
radiation is yet another risk factor and is related to both cellular sensitivity 
and to microscopic and macroscopic anatomy. Cells of different tissues 
demonstrate different response rates to the same radiation dose. Early or late 
radiation response reflects different cell turnover rates. Rapidly dividing 
self-renewing tissues respond early to the effects of radiation; examples are 
skin, hair follicles, intestinal epithelium and bone-marrow. Late-responding 
tissues are tissues with a slow cell turnover like the spinal cord, lungs, bone 
and kidneys (102).  
Radiation side effects may be induced in all normal cells and structures that 
are included in the treatment volume. Even the smallest volume the GTV, 
contains normal tissue elements like blood vessels and connective tissue 
Normal tissues radiation sensitivity may significantly influence treatment 
planning and/or prescribed dose. The normal tissues at risk during RT are 
defined as organs at risk (OAR). The tissue radiation tolerance has been 
explained by Withers et al in 1988 on the base of functional subunits 
(FSUs). Per definition, a FSU is the minimum unit that can function 
independently of the remaining organ. The clinical consequence after 
radiation depends on the arrangement of FSUs within the exposed OAR. 
OARs are classified as serial, parallel, or mixed serial-parallel. In parallel 
organs, FSUs can be damaged without harming global organ function, since 
other regions maintain function. Examples are lung, liver and kidney. 
Typically, there is little effect on global organ function until a “critical 
volume” of the organ is affected, at which point, global organ function can 
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be impaired. The response of a parallel organ to radiation depends on the 
volume of affected organ (103). 
In the matter of serial organs, the function of the entire organ depends on 
the function of each individual FSU; local damage to only one FSU can 
affect the whole organ and make it dysfunctional. This may be the case for 
nerves, intestines and oesophagus. The response of a serial organ to 
radiation is highly dependent on the maximum dose delivered to the organ. 
The dose distribution within the organ is of less relevance. 
In reality most organs are not probably not either serial or parallel but to 
some degree mixed. The normal tissue reaction to radiation depends also on 
the endpoint. As an example considering the endpoint “stricture”, the bowel 
is considered a serial organ but considering the endpoint bleeding it is 
regarded as a parallel organ. OARs routinely considered during prostate RT 
are the bladder, rectum, penile bulb and femoral heads (102;103).  
Dose-volume histograms (DVHs) (shown in figure 6) are histograms 
relating radiation dose to tissue volume in radiation therapy planning. In 
modern radiation therapy, 3D dose distributions are typically created in a 
computerized treatment planning system based on a 3D reconstruction of a 
CT scan. DVH summarizes 3D dose distributions in a graphical 2D format. 
The "volume" referred to in DVH analysis is a target of radiation treatment, 
a healthy organ nearby a target, or an arbitrary structure. DVH metrics 
correlate with patient toxicity outcomes 
Normal tissue complication probability models (NTCP) have been made to 
try to predict the probability that a given radiation dose will lead to damage 
of normal tissue, based on the specific biological cells (i.e.organised in 
parallel, serial or combined FSUs). The NTCP models try to reduce 
complicated dosimetric and anatomic information to a single risk measure 
that can be used in a clinical setting. The NTCP estimates are population 
based, thus a low risk estimate does not exclude the occurrence of normal 
tissue injury, possibly severe in any individual patient (102). 
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Figure 6: Dose-volume histogram. A DVH used clinically usually includes 
all structures and targets of interest in the radiotherapy plan, each line 
plotted a different colour, representing a different structure.  
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CHAPTER 5. AIMS OF THE PROJECT  
The aim of this Ph.D. thesis was to explore a new treatment modality using 
MRI target planning and a Ni-Ti prostate stent as fiducial marker for both 
MR-CT co-registration and IGRT in prostate cancer RT. The thesis was 
planned as the long-term follow-up of this relatively new treatment set-up in 
search of better target planning before therapy and visualization during 
therapy; eventually to try to optimize treatment results but minimize 
treatment related side-effects. The scopes were: 
- To evaluate 5 year follow-up in terms of survival, toxicity and QoL 
outcomes using a Ni TI prostate stent as fiducial marker. 
- To evaluate MRI target delineation in prostate cancer compared to 
CT delineation in clinical practice. 
- To assess 3 and 5 year toxicity and QoL in PCa patients after high-
dose IGRT using MRI target delineation and the prostate stent as 
fiducial or standard CT delineation and standard gold markers as 
fiducials. 
- To explore potential clinical and dosimetric risk factors for 
development of toxicity after EBRT. 
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CHAPTER 6. MATERIAL AND 
METHODS 
In the following section the material and methods used in paper 1-4 will be 
briefly described. Detailed description of material and methods are 
presented in the individual papers. The scoring systems used in the studies 
are described in more details. 
 
6.1. TOXICITY SCORING 
 
Toxicity induced by prostate cancer treatments are typically expressed in the 
gastrointestinal or urinary tract. Urinary, bowel and sexual dysfunctions are 
often observed after treatment for EBRT for PCa and may impact on the 
patients’ quality of life (104-106). Several questionnaires and scoring 
schemes have been used internationally to score prostate cancer treatment-
related toxicity like the Radiation Therapy Oncology Group (RTOG), the 
Expanded Prostate Cancer Index, the Late Effects in Normal Tissue 
Subjective, Objective and Analytic scales (LENT SOMA), and the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTC-
AE). The different scoring systems with their variations in scoring scales 
and endpoints often make comparisons of toxicity from different study 
publications difficult. The RTOG score is widely used  
(57;58;91;99;104;105;107;108), but looses specificity when reporting 
toxicity while the score scheme summarizes the symptom scores into a 
single grade instead of keeping the different symptoms separate. Interesting 
and important information can be hidden in the single grade. 
In the present studies toxicity was assessed primarily using the CTC-AE 
version 4.0 schemes. The National Cancer Institute defines an adverse event 
as any unfavourable and unintended sign, symptom, or disease temporally 
associated with the use of a medical treatment or procedure that may or may 
not be considered related to the treatment or procedure (109).  
Grade refers to the severity of the adverse effect (AE). The CTC-AE 
displays Grades 1 through 5 with clinical descriptions of severity for each 
AE based on the following general guideline. A semi-colon indicates ‘or’ 
within the description of the grade. 
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Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental ADL*. 
Grade 3: Severe or medically significant but not immediately life-
threatening; hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self care ADL**. 
Grade 4: Life-threatening consequences; urgent intervention indicated. 
Grade 5: Death related to AE. 
Activities of Daily Living (ADL) are defined as the following: 
*Instrumental ADL refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc. 
**Self care ADL refer to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden. 
The rectal symptoms investigated in the studies were stool frequency, stool 
incontinence, rectal pain, proctitis, rectal pain and rectal bleeding. The 
urinary symptoms included frequency, urgency, incontinence, dysuria, 
urinary retention and haematuria. Late complications were defined as those 
developing ≥6 months after RT completion. Peak toxicity scores were 
registered, even in the case of full recovery. 
Potential risk factors predicting both late gastrointestinal (GI) and 
genitourinary (GU) toxicity have been the subject to several studies. 
Concerning GI toxicity the symptom rectal bleeding is often studied, 
probably because of its objectivity but may not be the most annoying 
symptom (110). Different studies have described large rectal volume and 
dose, acute GI an GU toxicity, haemorrhoids, diabetes, advanced age, 
previous abdominal surgery, inflammatory bowel disease as risk factors 
(98;111-116). 
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With regard to GU toxicity large prostate volume, large radiation volume 
and dose, prior transurethral resection of the prostate (TUR-P) or bladder 
tumour (TUR-B) are recognized as risk factors (91;117;118).  
6.2. QUALITY OF LIFE ASSESSMENTS 
Historically, the management of cancer disorders has focused almost 
exclusively on the clinical outcome and clinician-reported measures of 
toxicity have been used to describe treatment side-effects. Today it has been 
recognized, that physician registered toxicity has the tendency to 
underestimate the impact of the symptoms (119). In recent years there has 
been an increased awareness that patient-reported outcomes like QoL are of 
great importance for men diagnosed with prostate cancer given that most 
men are diagnosed at an early stage and live for many years after treatment. 
Also due to the range of treatment options available with similar survival 
outcomes and the differential effects of various treatments on patients’ 
symptoms and functional health, QoL assessment may play an even greater 
role in treatment decision-making for the prostate cancer patient than for 
some other types of cancer (120). Different questionnaires have been 
developed to assess health related (HR) QoL. The two probably best known 
questionnaires are the Functional Assessment of Cancer Therapy (FACT) – 
mostly used in the USA and the European Organization for Research and 
Treatment of Cancer (EORTC) – mostly used in Europe (121). The EORTC 
approach (122) includes a core questionnaire, the QlQ-C30 designed to 
measure physical, psychological, and social functioning of patients with 
cancer. It incorporates five functional scales (physical, role, cognitive, 
emotional, and social functioning); three symptom scales (fatigue, pain, and 
nausea and vomiting); and a global health and QoL scale. The remaining 
single items assess additional symptoms that are commonly reported by the 
patient: dyspnoea, appetite loss, sleep disturbance, constipation, and 
diarrhoea and the perceived financial effect of the disease and treatment. 
The core questionnaire can be supplemented with a disease specific module, 
in the case of PCa: the QLQ-PR25 prostate module developed by the 
EORTC Genito-Urinary Tract Cancer Cooperative Group. This module 
consists of 25 questions and assesses urinary, bowel and sexual symptoms 
as well as symptoms related to hormonal treatment. 
Each item scores from 1= not at all to 4= much, with the exception of the 
two overall QoL questions in the C30 questionnaire that scores from 1= 
very poor to 7= excellent. For ease of statistical interpretation and 
psychometric validation, all scale and item scores are linearly transformed 
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to a scale from 0 to 100. For the five functional scales and the global 
quality-of-life scale, a high score represents a good level of functioning. For 
the symptom scales and items, a high score corresponds to more severe 
symptoms. 
 
6.3. PATIENT POPULATION 
All patients included in the studies had biopsy verified localized or locally 
advanced PCa and were treated with IGRT at the department of Oncology, 
University Hospital of Aalborg from March 2007 to May 2009. The 
diagnosis and staging were performed at the local department of Urology 
prior to referral to the department of Oncology. The study population 
consisted of two groups of PCa patients. One group of 100 patients 
participated voluntarily in a phase 3 trial evaluating the NI-TI stent for MR-
CT co-registration and as fiducial marker for IGRT (MR group) (76). 
Another consecutive group of 102 prostate cancer patients had standard 
planning CT and gold markers as fiducials during the same period (CT 
group). The patients were identified through searches in the patient radiation 
databases at the department of Oncology, Aalborg Hospital. Reasons for 
exclusion from toxicity and QoL assessments were death, biochemical 
failure (PSA nadir +2 ng/ml) and limited Danish skills. The exclusion of 
patients with biochemical failure was to avoid bias from either disease 
recurrence or salvage therapy. The assessments were made for the 
individual patient 3 and 5 years after their RT. Data regarding clinical and 
dosimetric parameters were retrieved from the hospital medical records.  
 
6.4. RADIOTHERAPY TREATMENT 
 
Patients had fiducials inserted in the prostate before dose planning imaging. 
Fiducials were either 3 gold markers or the Nickel-Titanium prostate stent. 
The gold markers were transrectally implanted. The prostate stent was 
endoscopically placed using local analgesics. Both procedures were 
performed at the local department of Urology.  
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Figure 7. 
a) The DS-II stent mounted on insertion kit and Foley catheter with balloon
inflated. 
b) Flouroscopy image from insertion. The Foley catheter is inflated with
contrast media. The bladder is filled with diluted contrast media to give the 
contour of the bladder. The insertion kit has been pushed forward until the 
upper end of the stent touches the Foley catheter balloon. The distance from 
the lower end of the stent to the caudal part of the pubic bone has to match 
the measure from the diagnostic MR scan. The catheter has been flushed 
with hot water and the stent collar has expanded and locked the stent 
position in the prostate. 
All patients had a planning CT scan (spiral scan slice thickness 2.5mm). 
Patients with the prostate stent inserted had an additional planning MR scan 
performed (1.5T or 3T MR T2 weighted images slice thickness 3mm, TR: 
5320ms, TE: 94.96ms, FOV: 300x300mm², matrix: 382x224). The CTV 
was defined as the prostate gland. In case of seminal vesicle invasion or risk 
of invasion (Partin tables) (50), the CTV was defined as the prostate gland 
plus the proximal third part of the seminal vesicles. For patients in the CT 
group the CTV was outlined on the planning CT alone. Patients in the MR 
group had CTV outlined on the MR scan. The MR scan was co-registered to 
the planning CT using manually inserted landmarks on the inserted stent. 
The CTV outlined on MRI was subsequently copied to the planning CT 
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before dose calculation. A planning target volume (PTV) was created using 
an isotropic PTV to CTV margin of 5mm. Treatment planning was based on 
a 3D conformal technique with five conformal fields at gantry angles 0, 90, 
140, 220 and 270 degree. Multi leave collimators were fitted until the 95% 
isodose encompassed the PTV. A dose of 2 Gy was prescribed to 100% 
isodose. Using 6 MV X-rays a total dose of 78 Gy was given in 39 fractions. 
The following constraints were used for normal tissue. Rectum V70≤25% 
(maximum 25% of the rectal volume should receive maximum 70Gy). 
V60≤50% and dorsal part of rectum received a maximum dose of 65 Gy. 
For the bladder V70≤35% and V60≤50% was used. For the femoral heads 
v52≤10% was used. Patients were treated lying supine with a knee and feet 
fixation. Using the inserted fiducials daily stereoscopic X-ray images were 
matched within 1-2 mm of CT reference digital reconstructed radiogram 
(DRR) images. After matching patients were automatically repositioned 
using the ExacTrac system with Robotics from Brainlab. The final position 
was verified daily using a new set of X-ray images before treatment was 
given.  
6.5. STATISTICAL METHODS 
Comparisons between participants and non-participants were made using 
the t-test or Mann-Whitney test for continuous variables and χ2 or Fisher’s 
exact test for categorical variables. These statistical tests were also used 
comparing patient characteristic and late toxicity scores between the CT and 
MRI treatment groups. We calculated time time-to-event curves from the 
end of RT, using Kaplan-Meier estimates. Log-Rank statistics was applied 
to test differences in survival and PSA-relapse free survival between the 
groups. The CT group was used as a reference when comparing the two 
treatment groups.  
The possible correlation between rectal bleeding and each of the 
investigated clinical parameters was analyzed first by univariate (UVA) 
logistic regression analysis. After this a stepwise multivariate logistic 
regression model was build to analyse further those clinical and dosimetric 
parameters that appeared to be associated with the endpoint in the primary 
UVA. The association was defined as parameters with p-values ≤0.20. The 
odds ratio (OR) was used to express the strength of association of a 
parameter with the considered endpoint. QoL data was scored according to 
the EORTC scoring manual (122). 
The p-values are two-sided, the significance level was set at 5%, 95% 
confidence intervals were calculated for the ORs. All analyses were carried 
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out using the statistical software package from Stata v.11 (Stata statistical 
software version 11; Stata Corporation). 
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CHAPTER 7. RESULTS 
A short summary of the results from the four papers are presented in the 
following. A detailed description of the results is presented in the individual 
papers 1-4. 
Paper 1 
MRI target delineation may reduce long-term toxicity after prostate 
cancer radiotherapy. 
Sander L, Langkilde NC, Holmberg M, Carl J 
Acta Oncologica 2014 
Summary 
Aiming for minimal toxicity after PCa RT, MRI delineation could be a 
possible tool, knowing that CTV are up to 30% smaller on MRI delineation 
compared to CT delineation. The study evaluated toxicity 3 years after high-
dose IG-RT comparing target planning delineation on MR and a prostate 
stent as fiducial  with CT target planning and the use of gold markers as 
fiducials. The treatments were performed with the same radiation dose and 
PTV margins. A significantly smaller CTV was found in the MR-group 
(40.9 vs. 52.1. cm³). The CTV was correlated to a reduction in overall rectal 
toxicity, but not to a reduction in overall urinary toxicity.  
In general the late side effects 3 years after RT were few and mild and 
comparable with the lowest toxicity rates reported in the literature. No grade 
3 toxicity was found. Significantly lower urinary frequency and urinary 
retention toxicity scores were observed following MRI delineation. No 
significant differences were found in overall urinary or rectal toxicity.  
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 ORIGINAL ARTICLE 
 MRI target delineation may reduce long-term toxicity after 
prostate radiotherapy 
 LOTTE  SANDER 1 ,  NIELS CHRISTIAN  LANGKILDE 1 ,  MATS  HOLMBERG 3  & 
 JESPER  CARL 2 
 1 Department of Urology, Aalborg University Hospital, Aalborg, Denmark,  2 Department of Medical Physics, Oncology, 
Aalborg University Hospital, Aalborg, Denmark and  3 Department of Oncology, Aalborg University Hospital, Aalborg, 
Denmark 
 ABSTRACT 
 Background and purpose. Aiming for minimal toxicity after radical prostate cancer (PC) radiotherapy (RT), magnetic 
resonance imaging (MRI) target delineation could be a possible beneﬁ t knowing that clinical target volumes (CTV) are 
up to 30% smaller, when CTV delineation on MRI is compared to standard computed tomography (CT). This study 
compares long-term toxicity using CT or MRI delineation before PC RT. 
 Material and methods. Urinary and rectal toxicity assessments 36 months after image-guided RT (78 Gy) using 
CTC-AE scores in two groups of PC patients. Peak symptom score values were registered. One group of patients (n    72) 
had standard CT target delineation and gold markers as ﬁ ducials. Another group of patients (n    73) had MRI target 
delineation and a nickel-titanium stent as ﬁ ducial. 
 Results. At 36 months no difference in overall survival (92% in both groups, p    0.29) or in PSA-relapse free survival 
was found between the groups (MRI    89% and CT    94%, p    0.67). A signiﬁ cantly smaller CTV was found in the 
MRI group (p    0.02). Urinary retention and frequency were signiﬁ cantly reduced in the MRI group (p    0.03 in the 
matter of both). The overall urinary and rectal toxicity did not differ between the two groups. 
 Conclusion. MRI delineation leads to a signiﬁ cantly reduced CTV. Signiﬁ cantly lower urinary frequency and urinary 
retention toxicity scores were observed following MRI delineation. The study did not ﬁ nd signiﬁ cant differences in 
overall urinary or rectal toxicity between the two groups. PSA-relapse survival did not differ between the two groups 
at 36 months. 
 Radiotherapy (RT) plays a key role in today ’ s treat-
ment of prostate cancer (PC). In several randomised 
trials dose escalation has shown to improve the bio-
chemical control, but it is also followed by an increase 
in toxicity [1 – 3]. RT-related toxicity in PC most 
commonly involves the urogenital and gastrointesti-
nal systems. Development of these toxicities is related 
to both the radiation dose to and the volume of nor-
mal tissue irradiated during the therapy [4,5]. Day-
to-day changes in patient position and variations in 
prostate position during the course of radiation are 
considered as sources of treatment errors. Prostate 
displacements of more than 10 – 15 mm have been 
documented [6]. To account for these positional 
changes a margin is added to the  clinical target vol-
ume (CTV) to assure sufﬁ cient dose coverage of the 
targeted tumour volume. This, however, increases the 
risk of over dosage of normal tissue and thereby 
 toxicity. The use of prostate markers enables a more 
exact target location and makes margin reduction 
possible [7]. Novel techniques like daily image-
guided radiotherapy (IGRT) are widely used com-
bined with prostate ﬁ ducials for daily prostate 
position veriﬁ cation and correction. This has led to 
a reduction in the observed toxicity [8,9]. 
 Currently, the most used method is implanted 
gold markers (GM) combined with treatment plan-
ning on computed tomography (CT). This method, 
however, has been shown to lead to an overestima-
tion of the prostate volume. Volumes up to 30% 
larger have been found on CT when compared to 
target delineation on MRI [10 – 12]. CT-MRI image 
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fusion-based treatment planning allows more accu-
rate prediction of the target volume [13,14]. The CT-
MRI co-registration can be done in several ways  – on 
bony landmarks, with endorectal coil or by intrapro-
static ﬁ ducial markers. Despite this, MRI-based 
planning has not yet replaced CT planning for 
routine PC RT. Studies are needed to evaluate 
whether the reduction in CTV on MRI is followed 
by a clinical relevant reduction in the long-term 
toxicity without compromising treatment failure. 
 The aim of this historical follow-up study was to 
evaluate the late (36 month) urinary and rectal tox-
icity among men with localised or locally advanced 
PC treated with RT at the Department of Oncology, 
Aalborg University Hospital between 2007 and 
2009. Comparisons were made between the stan-
dard treatment (planning CT/GM) and a new treat-
ment modality using MRI delineation, CT-MRI 
co-registration and a Nickel-Titanium (Ni-Ti) stent 
as prostate marker [15]. 
 Material and methods 
 Patient population 
 Included in this non-randomised historical follow-up 
study were patients with localised or locally advanced 
PC (T1-T3N0M0) who completed RT with curative 
intent at the Department of Oncology, Aalborg 
 University Hospital between March 2007 and May 
2009. During this period, a group of 100 patients 
participated voluntarily in a phase III trial evaluating 
a Ni-Ti stent for MRI-CT co-registration and as 
 ﬁ ducial marker (MRI-group) [15]. Another consecu-
tive group of 102 PC patients had standard planning 
CT and GMs as ﬁ ducials during the same period 
(CT-group). 
 The patients were identiﬁ ed through searches in 
the patient radiation databases at the Department of 
Oncology, Aalborg Hospital. 
 Reasons for exclusion were death, biochemical 
failure (PSA nadir   2 ng/ml) and inability to read 
and understand the questionnaires in Danish. The 
study was approved by the Regional Committee for 
Medical Research Ethics. 
 Toxicity assessment 
 All eligible men received a mailed invitation to par-
ticipate in the study including information about the 
study, a consent form and a questionnaire. All par-
ticipants completed and returned the consent form 
and questionnaire in a prepaid envelope. 
 The patients that returned the consent form and 
questionnaire were contacted for a telephone inter-
view and toxicity regarding urinary and rectal symp-
toms was assessed. All the patients were contacted 
by one doctor or one research nurse. 
 The late toxicity assessment was made for 
the individual patient three years after his RT. Late 
complications were deﬁ ned as those developing 
   6 months after RT completion. Peak toxicity scores 
were registered, even in the case of full recovery. 
Toxicity was assessed using the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTC-AE) version 4.0. Rectal symptoms 
included stool frequency, stool incontinence, rectal 
pain, proctitis, rectal pain and rectal bleeding. Uri-
nary symptoms included frequency, urgency, incon-
tinence, dysuria, urinary retention and haematuria. 
 Data regarding clinical parameters like Gleason 
score, tumour stage, presenting PSA level, prostate 
volume, medications and co-morbidity (including 
haemorrhoids) were retrieved from the medical 
hospital records. 
 Treatment 
 Men with medium and high risk disease according 
to the D ’ Amico classiﬁ cation [16] received neo-
adjuvant endocrine treatment with either LHRH 
analogues or non-steroidal anti-androgens for three 
months before irradiation. Endocrine treatment was 
continued during irradiation and for a limited period 
thereafter, usually for one year according to the rec-
ommendations in Denmark at that time. 
 Patients had ﬁ ducials inserted in the prostate 
before dose planning imaging. Fiducials were either 
three GMs or a Ni-Ti prostate stent. All patients had 
a planning CT scan (spiral scan slice thickness 2.5 
mm). Patients with the prostate stent inserted had an 
additional planning MRI scan performed (1.5T or 
3T MR T2 weighted images slice thickness 3 mm, 
TR: 5320 ms, TE: 94.96 ms, FOV: 300    300 mm ² , 
matrix: 382    224). The CTV was deﬁ ned as the 
prostate gland. In case of seminal vesicle invasion or 
risk of invasion (Partin tables) [17], the CTV was 
deﬁ ned as the prostate gland plus the proximal third 
part of the seminal vesicles. For patients in the CT 
group the CTV was outlined on the planning CT 
alone. Patients in the MRI group had CTV outlined 
on the MRI scan. The MRI scan was co-registered 
to the planning CT using manually inserted land-
marks on the inserted stent. The CTV outlined on 
MRI was subsequently copied to the planning CT 
before dose calculation. 
 A planning target volume (PTV) was created 
using an isotropic PTV to CTV margin of 5 mm. 
Treatment planning was based on a 3D conformal 
technique with ﬁ ve conformal ﬁ elds at gantry 
angles 0, 90, 140, 220 and 270 degree. Multi leave 
collimators were ﬁ tted until the 95% isodose 
encompassed the PTV. A dose of 2 Gy was pre-
scribed to 100% isodose. Using 6 MV x-rays a total 
dose of 78 Gy was given in 39 fractions. The 
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 following constraints were used for normal tissue. 
Rectum V70    25% (maximum 25% of the rectal 
volume should receive maximum 70 Gy). V60    50% 
and dorsal part of rectum received a maximum dose 
of 65 Gy. For the bladder V70    35% and V60    50% 
was used. For the femoral heads v52    10% was 
used. Patients were treated lying supine with a knee 
and feet ﬁ xation. Using the inserted ﬁ ducials daily 
stereoscopic x-ray images were matched within 1 – 2 
mm of CT reference digital reconstructed radio-
gram (DRR) images. After matching patients were 
automatically repositioned using the ExacTrac sys-
tem with Robotics from Brainlab. The ﬁ nal position 
was veriﬁ ed daily using a new set of x-ray images 
before treatment was given. 
 Statistical methods 
 Comparisons between participants and non-partici-
pants were made using the t-test or Mann-Whitney 
test for continuous variables and  χ 2 or Fisher ’ s exact 
test for categorical variables. These statistical tests were 
also used comparing patient characteristic and late 
toxicity scores between the CT and MRI treatment 
groups. We calculated time time-to-event curves from 
the end of RT, using Kaplan-Meier estimates. Log-
rank statistics was applied to test differences in survival 
and PSA-relapse free survival between the groups. The 
CT group was used as a reference when comparing 
the two treatment groups. P-values are two-sided and 
statistical signiﬁ cance was set at 5%. Univariate and 
multivariate logistic regression was used for subgroup 
analysis. The data were analysed using STATA v11 
(Stata statistical software version 11; StataCorp). 
 Results 
 Two hundred and two patients underwent curatively 
intended RT during the deﬁ ned period. A total of 
145 men returned the consent form and participated 
in the study. There were no signiﬁ cant differences 
between participants and non-participants with 
regard to patient characteristics or tumour character-
istics except that T-stages were higher in the group 
of participants (p    0.05) (data otherwise not shown). 
Patient ﬂ ow is shown in Figure 1. 
 Follow-up time for all participants was 36 months. 
Baseline patient characteristics are presented in Table I. 
The two groups were comparable in the matter of age, 
Gleason score, pre-treatment PSA, inclusion of seminal 
vesicles in CTV, smoking, diabetes and medications. 
Higher T-stages and risk classiﬁ cation were present in 
the MRI group. No signiﬁ cant difference in overall sur-
vival was found at 36 months (CT group    92% and 
MRI group    92%, p    0.29). The PSA failure free sur-
vival did not differ signiﬁ cantly either (CT group    94% 
and MRI group    89%, p    0.67). 
 The prostate volume was found to be 21.5% 
smaller in the MRI group than in the CT group with 
mean volumes of 40.9 cm 3 and 52.1 cm 3 , respec-
tively (p    0.02). In general the late side effects within 
the ﬁ rst three years after RT were few and mild in 
both groups. No grade 3 toxicity was registered. The 
results for the peak toxicity scores concerning rectal 
and urinary symptoms are presented in Tables II 
and III, respectively. Comparisons between the 
maximum overall scores of late rectal and urinary 
toxicities observed are made in Table IV, these do 
not differ signiﬁ cantly between the groups (p    0.4 
and 0.5, respectively). 
 With regard to rectal symptoms, grade 2 toxicity 
was registered only concerning  “ rectal bleeding ” and 
in only four patients in total. The one patient from 
the MR group with grade 2 rectal bleeding was sub-
sequently diagnosed with ulcerative colitis subse-
quent the RT. No signiﬁ cant differences were found 
concerning rectal symptoms between the two groups. 
There was no inﬂ uence of age, T-stage, Gleason 
score, pre-treatment PSA, seminal vesicles irradia-
tion, anticoagulants, smoking or statin-use on the 
development of rectal symptoms. 
 Urinary toxicity was predominantly manifested 
as increased frequency and urgency symptoms 
requiring  α -blocker medications. No difference in 
overall urinary toxicity was found. Looking at the 
speciﬁ c toxicity a statistically signiﬁ cant difference 
between the two groups was found with respect 
to  “ frequency ” and  “ urinary retention ” (p    0.03 
in the matter of both). No correlation was found 
between overall urinary toxicity and CTV. No 
apparent inﬂ uence of age, T-stage, Gleason score, 
pre-treatment PSA, anticoagulants, smoking or 
 Figure 1. Patient ﬂ ow. Fourteen were lost to follow-up (11 from 
the Faroe Islands, three from other Danish regions). Ineligible 
were two patients because of non-standard RT treatment, two 
because of language problems, one because of PSA failure during 
RT (metastatic disease). PSA failure    nadir    2 ng/ml. 
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diabetes on the development of urinary symptoms 
was seen. 
 Discussion 
 To our knowledge, this is the ﬁ rst report to compare 
toxicity in patients with localised or locally advances 
PC treated with IGRT using target planning delinea-
tion on either MRI or CT. The comparison is of value 
in that both groups were treated with the same radi-
ation dose and with similar margins for the PTV. The 
difference between the two groups, were whether the 
target planning was based on MRI or CT delineation 
and whether a three-dimensional Ni-Ti stent or three 
GMs were used as ﬁ ducials for daily positioning 
veriﬁ cation. We observed, as expected, a smaller 
CTV volume in the MRI-delineated prostates. The 
CTV was correlated to a reduction in overall rectal 
toxicity but not correlated to a reduction in overall 
 Table III. Urinary toxicity. 
Grade MRI CT Total
Haematuria 0 66 67 133 p    1.0
1 6 5 11
2 1 0 1
Frequency 0 47 36 83 p    0.03
1 16 30 46
2 10 6 16
Urinary retention 0 70 61 131 p    0.03
1 3 11 14
2 0 0 0
Urethral pain 0 69 70 139 p    0.7
1 4 2 6
2 0 0 0
Urgency 0 40 43 83 p    0.7
1 23 21 44
2 10 8 18
Incontinence 0 68 66 134 p    0.9
1 5 5 10
2 0 1 1
 Table I. Patient characteristics. 
MRI CT
Age (range) 70.5 (62 – 80) 70.1 (58 – 78) p    0.5
T-stage (%)
T1 9 (12) 26 (36) p    0.003
T2 28 (38) 14 (19)
T3 36 (49) 31 (43)
T4 0 1 (1)
Gleason score (%)
6 11 (15) 3 (4) p    0.19
7 52 (71) 58 (81)
8 5 (7) 6 (8)
9 4 (5) 5 (7)
10 1 (1) 0
Risk (d ’ Amico classiﬁ cation) (%)
Low 4 (5) 1 (1) p    0.02
Intermediate 18 (25) 33 (46)
High 51 (70) 38 (53)
Pretreatment PSA
Mean (range) 15.5 (4.1 – 67) 14.6 (0.6 – 67) p    0.23
Seminal vesicles in CTV (%) 9 (12) 10 (14) p    0.78
Hormonal therapy (%) 69 (95) 69 (96) p    0.19
Nicotine (%) 17 (23) 15 (21) p    0.79
Diabetes (%) 10 (14) 11 (15) p    0.44
Use of antikoagulantia (%) 10 (14) 9 (13) p    0.83
Haemorrhoids (%) 5 (7) 4 (6) p    0.75
Medications
No drugs 12 (16) 13 (18) p    0.92
   5 different drugs 45 (62) 42 (58)
Polyfarmaci (   5) 16 (22) 17 (24)
 Table II. Rectal toxicity. 
Grade MRI CT Total
Diarrhoea 0 68 63 131 p    0.3
1 5 9 14
2 0 0 0
Faecal incontinence 0 68 68 136 p    0.7
1 5 4 9
2 0 0 0
Proctitis 0 68 67 135 p    0.9
1 5 5 10
2 0 0 0
Rectal bleeding 0 53 44 97 p    0.3
1 19 25 44
2 1 3 4
Rectal pain 0 73 72 145
1 0 0 0
2 0 0 0
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urinary toxicity. However, the number of patients 
that experienced urinary frequency and urinary 
retention differed signiﬁ cantly between the two 
groups. The overall incidences of both late rectal and 
urinary toxicities showed a trend towards less toxicity 
in the MRI group though not signiﬁ cant. 
 Late grade 2 urinary toxicity was observed in 
16.4% (MRI) and 12.5% (CT) of the patients. These 
results are consistent with the results in resent pub-
lications like those of Zelefsky (10.4%, IGRT, 86.4 
Gy) [18] and Crehange (7%, IMRT, 74 – 78 Gy) [19]. 
With regard to late grade 2 rectal toxicity our ﬁ nd-
ings at 1.4% (MRI) and 4.2% (CT) are also compa-
rable with Zelefsky (1%) and Crehange (1.2 %). 
 The contouring variation seen with MRI is lower 
than with CT because of the superior distinction of 
the prostate from adjacent structures on MRI. How-
ever, with training, these structures can many times 
be recognised on CT scans as well [11]. This may 
explain that we have found a difference of  “ only ” 
21.5% between the MRI-delineated prostate vol-
umes and the CT-delineated volumes, whereas oth-
ers have found differences above 30%. The similar 
toxicities between the two groups found in this study 
may also be a result of this. 
 Albeit we did not observe a reduction in late rectal 
toxicity, this might be explained by the low rectal tox-
icity incidence with IGRT in general. A larger patient 
population would be required to demonstrate a differ-
ence in rectal toxicity between the groups. The strong 
correlation between CTV and rectal bleeding and the 
ﬁ nding of a smaller CTV in the MRI group in this 
study sustain this theory. Other studies have evaluated 
rectal dose-volume histograms and found consistent 
results on the dose-volume effect on the probability of 
developing rectal bleeding [20,21]. Both the absolute 
and the percentage of rectal volume receiving the 
highest doses (   60 Gy) are correlated with rectal 
bleeding [22]. As the CTV increases a larger volume 
of the rectum is at risk of high dose irradiation thus 
explaining the increased risk of rectal bleeding. 
 There is a delicate balance between the aim of 
maximum accuracy and PTV margin reduction to 
avoid normal tissue toxicity, and the risk of missing 
microscopic extra prostatic tumour extension as con-
sequence of irradiated target volume reduction. The 
exact incidence and extent of microscopic disease 
remains uncertain because of imaging modalities 
limitations, but is known to be correlated with cer-
tain pre-treatment characteristics like PSA, T-stage 
and Gleason score [23]. A recent study from Heems-
bergen et  al. [24] has reported fewer clinical failures 
for high-risk PC patients treated with rectangular 
ﬁ elds, compared to conformal ﬁ elds underlining the 
above mentioned problem. Patient recruitment took 
place in the period 1994 – 1996, thus in another era. 
Imaging modalities have improved signiﬁ cantly since 
and androgen deprivation therapy in combination 
with RT is standard treatment of high-risk PC 
patients today. However, the authors raise a relevant 
question: Maybe margins can be too tight, thus com-
promising clinical failure and in the end survival. In 
that case higher toxicity rates would be acceptable, if 
the patients gain in terms of prolonged survival. 
 Limitations of this study include the relatively 
short follow-up time and that it is a historical fol-
low-up design. A prospective design, especially with 
baseline assessments before RT, would be preferable 
to evaluate changes in late toxicity. In the matter of 
long-term toxicity registrations, some of the symp-
toms may be due to undetected co-morbidity pro-
gression. This may be particularly relevant in an 
elderly patient population like PC patients. Age-
matched control groups are known to be affected by 
signiﬁ cant urinary problems [25]. These consider-
ations are, however, of less signiﬁ cance in this study, 
as we compared two patient groups with similar 
baseline assessments. 
 This study includes a relatively low number of 
patients. Furthermore, we observed a very low num-
ber of patients with   grade 2 toxicity, and this lim-
its the statistical power. 
 MRI delineation and MRI-CT co-registration is 
today feasible as part of IGRT treatment for PC. 
We have presented the ﬁ rst data from our institu-
tion reporting 36-month toxicity after RT using 
MRI delineation for target planning. The effect of 
MRI delineation will require further conﬁ rmation 
with future prospective studies on more patients 
with longer follow-up time to evaluate the clinical 
relevance in terms of possible toxicity reduction. 
MRI delineation using the stent as ﬁ ducial is a 
costly and time consuming procedure, and there-
fore only recommendable if relevant toxicity reduc-
tion is obtained. 
 Future perspectives using the Ni-Ti stent as ﬁ du-
cial might also include sparing of the urethra. Dose 
exposure to the urethra and bladder neck attributes 
to the urinary toxicities. Urethra sparing with IMRT 
have so far been considered controversial because of 
 Table IV. Late overall rectal and urinary toxicity. 
Grade
MRI (n    73) CT (n    72)
p-valuen % n %
Rectal
0 46 63 39 54.1 0.4
1 26 35.6 30 41.7
2 1 1.4 3 4.2
Urinary
0 29 39.7 25 34.7 0.5
1 32 43.8 38 52.8
2 12 16.4 9 12.5
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concerns for under dosage of the periurethral tissue. 
A theoretical study suggests preserved tumour con-
trol using the Ni-Ti stent as ﬁ ducial combined with 
IMRT [26]. 
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Summary 
The potential correlation between different clinical and dosimetric 
parameters and the symptom “rectal bleeding” was investigated in the total 
study population. This was done by univariate and multivariate logistic 
regression analyzes. Toxicity results 3 years after RT was used. Analyzes 
were made for grade ≥1 rectal bleeding due to a very low number of grade 2 
rectal bleeding (4 patients). A cumulative incidence of 33% was found.  
Dmax, Dmean, Dmin2cc, V60Gy, V72Gy, smoking, T-stage, age and CTV 
seemed to be correlated with the endpoint at the UVA. The final MVA 
showed a robust statistically significant correlation between rectal bleeding 
and CTV (OR=1.01 per unit change, p=0.03). The potential correlation 
disappeared for the other investigated parameters. 
Of the parameters analyzed in this study, increasing CTV was found to be 
the only really robust predictor for late rectal bleeding with odds ratio of 
1.01 per unit change. 
LONG-TERM FOLLOW-UP AFTER MODERN RADICAL PROSTATE CANCER RADIOTHERAPY 
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Abstract  
Introduction: 
The aim of this study was to evaluate the role of different clinical and dosimetric parameters influence on 
late rectal bleeding after prostate cancer radiotherapy. 
Materials and methods: 
Toxicity was assessed 36 months after radical prostate radiotherapy (78Gy/39f) in 145 patients treated at the 
Hospital of Aalborg between May 2007 and May 2009. Toxicity was recorded using Common Terminology 
Criteria for Adverse Events for rectal bleeding. Analyzes were made for grade ≥1 toxicity. The correlation 
between different clinical and dosimetric parameters was investigated by univariate (UVA) and multivariate 
(MVA) logistic regression analyzes. 
Results: 
A cumulative incidence of 48/145 (33%) was found. CTV was found to be correlated with rectal bleeding at 
UVA (OR=2.57 per unit change, p=0.01). Among the other parameters only age and smoking appeared to be 
associated with rectal bleeding (OR=0.94 per year, p= 0.08 and OR=0.39, p= 0.06, respectively) at UVA. 
MVA showed a statistically significant correlation between rectal bleeding and CTV (OR=2.96, p=0.01), 
smoking (OR=0.35, p=0.04) and age (OR=0.9, p=0.01). 
Conclusion: 
At 3 years a cumulative incidence of 33% was observed for grade 1-2 rectal bleeding. The analysis 
highlighted CTV as a major risk factor. Smoking showed a protective effect against the development of 
rectal bleeding.  There seemed to be a discrete protective effect of age. The other clinical factors: BMI, pre-
treatment PSA, diabetes, cardiac heart disease, poly-farmacia and anti-coagulants seemed to have no 
predictive power. 
Article text: 
Introduction: 
Despite advances in prostate cancer (PC) radiotherapy (RT) techniques e.g. the use of 3D conformal 
radiotherapy and image-guided RT (IGRT), a significant proportion of patients still suffer from long-term 
RT-induced gastrointestinal (GI) symptoms [1,2]. These symptoms include rectal bleeding, stool frequency, 
proctitis and fecal incontinence, symptoms that are known to influence patient satisfaction and quality of life 
[3,4]. Rectal bleeding has been one of the most studied endpoints after external RT for prostate cancer 
probably because of its frequency and objectivity. Late injury of the rectum most often occurs within the first 
2-4 years [5] after treatment. The origin of the lesion that results in rectal bleeding is poorly understood and 
unlike many other late complications, which persist or progress, rectal bleeding can fluctuate and even 
resolve spontaneously [6]. But even as a single event, an episode with rectal bleeding can influence on the 
patient’s quality of life and cause significant anxiety. 
Several studies have described a dose-response relationship concerning dosimetric factors like total dose, 
dose per fraction, volume irradiated and irradiation site and the development of rectal toxicity [5,7,8]. There 
is a growing recognition that individual clinical parameters like age, BMI, co-morbidity, medication and 
smoking history can influence the toxicity risk. Identification of the relevant parameters and incorporation of 
these into dose-volume based models will most probably improve the prediction of toxicity. 
It has been hypothesised that variation in late toxicity between individuals may be due to genetic variation 
[9]. Exploring such potential genetic factors it will be necessary to know and adjust for potential non-genetic 
risk factors. For patients who receive radiotherapy, prediction of late toxicity may help in introducing 
preventive procedures or planning corrections to better individualise the treatment to avoid toxicity.  
The aim of this study was to evaluate the role of different clinical and dosimetric parameters influence on 
late rectal bleeding after external RT for prostate cancer (PC). 
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Material and methods: 
Patient population 
A total of 202 patients with localised or locally advanced PC (T1-T3N0M0) were treated with radical RT at 
the department of Oncology, Aalborg University Hospital between March 2007 and May 2009. For the 
purpose of this study data were retrieved from a non-randomized historical follow-up study looking at 
toxicity and quality of life after radical RT focusing on MRI versus CT target delineation for RT dose 
planning on this patient group. Final analyzes refereed to 145 patients (reference til egen artikel!) The 
toxicity data on rectal bleeding were used in this study. The study was approved by the Regional Committee 
for Medical Research Ethics in accordance with the Helsinki Declaration II.  
Radiotherapy technique  
Men with intermediate and high risk disease according to the D’Amico classification [10] received neo-
adjuvant endocrine treatment with either luteinizing hormone-releasing hormone analogues or non-steroidal 
anti-androgen for 3 month before irradiation. Endocrine treatment was continued during irradiation and for a 
limited period thereafter, usually for 1 year according to the recommendations in Denmark at that time. 
Patients had fiducials inserted in the prostate prior to dose-planning imaging was performed. Fiducials were 
either gold markers or a Nickel-Titanium prostate stent. The prostate stent was removed 3 months after 
radiotherapy. The clinical target volume (CTV) was defined as the prostate gland. In case of seminal vesicle 
invasion or risk of invasion (Partin tables) [11], the CTV was defined as the prostate gland plus the proximal 
third part of the seminal vesicles. A planning target volume (PTV) was created using an isotropic PTV to 
CTV margin of 5mm. Treatment planning was based on a 3D conformal technique with five conformal 
fields. A dose of 78 Gy was given in 39 fractions in total. The department's standard constraints were used 
(rectum V70<=25%, V60<=50% and dorsal part of rectum Dmax<65 Gy). The rectum was defined and 
delineated from just above the anal verge to the recto-sigmoid flexure.  IGRT was performed using the 
inserted fiducials and daily stereoscopic X-ray images, matched within 1-2mm of CT reference digital 
reconstructed radiogram (DRR) images. Patients were automatically positioned using the ExacTrac system 
with Robotics from Brainlab. The final position was verified using a new set of X-ray image before 
treatment was given.  
Clinical endpoint 
In this analysis the incidence of late rectal bleeding was the clinical endpoint. Bleeders were defined as 
patients with ≥ grade 1 bleeding at any time after 6 months after radiotherapy completion, even in the case of 
full recovery.  
Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.0. Grade 1: mild; intervention not indicated. Grade 2: moderate symptoms, medical 
intervention or minor cauterization indicated. Grade 3: transfusion, radiologic, endoscopic, or elective 
operative intervention indicated. 
Data was collected by one doctor or one research nurse during a telephone interview or were retrieved from 
the hospital medical records. Clinical parameters considered were Gleason score, tumour stage, pre-treatment 
PSA, prostate volume (CTV), age, BMI, seminal vesicles irradiation, co-morbidities (e.g. diabetes and 
cardiac heart disease), smoking (during radiotherapy), poly-farmacia (>5 different medications) and the use 
of anti-coagulants. The dosimetric parameters considered for each patient were rectal volume, maximum and 
mean rectal distribution doses, the percent fraction of the rectum receiving more than 60 and 72GY (named 
V60 and V72) and the minimal dose given to the rectal area of 5cm³ that received the highest total dose 
(named Dmin2cc).  
Statistics 
The possible correlation between rectal bleeding and each of the investigated clinical parameters was 
analyzed first by univariate (UVA) logistic regression analysis. After this a stepwise multivariate logistic 
regression model was build to analyse further those clinical and dosimetric parameters that appeared to be 
associated with the endpoint in the primary UVA. The association was defined as parameters with p-values 
≤0.20.  
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The odds ratio (OR) was used to express the strength of association of a parameter with the considered 
endpoint. The p-values are two-sided, the significance level was set at 5%, 95% confidence intervals were 
calculated for the ORs. All analyses were carried out using the statistical software package from Stata v.11 
(Stata statistical software version 11; Stata Corporation) 
Results: 
Patient characteristics are shown in table 1. None of the patients had symptoms of rectal bleeding before 
radiotherapy. No grade 3 or worse late toxicity have been observed. Concerning grade 1 or 2 rectal bleeding 
we found a cumulative incidence of 44 patients with grade 1 and only 4 patients with grade 2 within 3 years 
after RT. Due to the low number of patients with grade 2 toxicity statistical analysis were made for the 
clinical outcome ≥ grade 1 toxicity.  A cumulative incidence of 48/145 (33%) was found for this outcome 
within 3 years after RT.  
The results from the primary UVA analysis are shown in table 2. Parameters that appeared to be associated 
with the outcome at the primary UVA was age, smoking, t-stage, CTV, Dmax, Dmean, Dmin2cc, V60Gy 
and V72G. In the subsequent MVA including the mentioned parameters from the UVA only CTV (OR=1.01, 
p=0.03) and age (OR=0.91, p=0.03) was found to be correlated with rectal bleeding (table 2). None of the 
other parameters showed even borderline significance. The association found at the UVA concerning the 
dosimetric parameters disappeared for all of them, when adjusting for the CTV. We looked at eventual 
outliers to check for the robustness of the multivariate regression model. When we did the MVA dropping 
the 2 youngest patients (both 55 years old), age does not show any significant association with rectal 
bleeding (OR=0.93, p=0.08). The CTV was the only really robust parameter that seemed correlated with the 
outcome.   
Discussion: 
The impact of clinical and dosimetric parameters as predictors of late rectal bleeding has been emphasised in 
recent literature.  
In this study we found a cumulative incidence of ≤ grade 1 rectal bleeding, 3 years after RT at 33%. This is 
comparable with the results of Koper, also reporting a 3 years cumulative incidence of rectal bleeding of 
33% [12].  
Of the parameters analyzed in this study, increasing CTV was found to be the only really robust predictor for 
late rectal bleeding with odds ratio of 1.01 per unit change (p=0.03). Several other studies have evaluated 
rectal dose-volume histograms and found consistent results of the dose-volume effect on the probability of 
developing rectal bleeding [5,12-15]. Both the absolute and the percentage of rectal volume receiving the 
highest doses (>60Gy) have been correlated with rectal bleeding. We found the same correlation in the UVA 
with regard to the parameters min2cc, V60Gy and V72Gy in the UVA. This correlation disappeared when 
adjusting for the CTV, leaving only the CTV to be significantly correlated with rectal bleeding in the final 
MVA.  As the CTV increases a larger volume of the rectum is at risk of high dose irradiation thus explaining 
the increased risk of rectal bleeding. The dose-volume data were calculated from one planning CT scan only, 
and we had no standard recommendations with regard to the rectal filling during RT. The rectum most 
probably has had different volumes during the 39 RT sessions for each patient and as a result the delivered 
rectal doses can differ significantly from the planned doses. This is probably one of the reasons why the 
correlation with regard to the dose-volume data disappears in the MVA. The CTV is, on the contrary, a 
consistent volume. 
Clinical factors that have been found to contribute to the degree of rectal bleeding after radical prostate 
radiotherapy include previous abdominal surgery, hemorrhoids, pre-existing diabetes mellitus, smoking, 
BMI, inactivity and age [12,15-21].  
In the primary UVA smoking seemed correlated with rectal bleeding (p=0.06), controversially showing a 
protective effect against rectal bleeding after radiotherapy. This correlation disappears in the multivariate 
analysis. But we found one earlier study describing the same correlation [12]. They found an association 
between smoking and less rectal bleeding (p=0.08) and report rectal blood loss for 37% of the non-smokers 
and 14% of the smokers. In our study the percentages were 37% (42/113) for non smokers and 18% (6/32) 
for smokers. However, a recent study by Thomas et al reported specified results concerning smoking and 
rectal bleeding but found no statistical significant association. With regard to inflammatory bowel disease it 
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is known that smoking protects the colon from inflammation. The exact mechanisms remain unclear. 
However, nicotine is assumed to be the active moiety and potential mechanisms may include changes in 
humoral and cellular immunity, changes in blood flow, colonic mucus and oxygen free radicals [22]. The 
same mechanisms may play a role in the case of smoking and rectal bleeding after radiotherapy.  
The findings in this study concerning the co-variate age are controversial, as there seem to be a minor 
protective effect (OR 0.91 per unit change) of age. The findings in other studies show conflicting results, 
some suggesting a positive association between age and rectal bleeding [16,19], others have shown no such 
association [20]. When we did our analysis controlling for outliers (dropping the 2 youngest patients) the 
correlation disappears, thus we conclude that the primary result is not valid, and that there is no correlation 
between age and rectal bleeding in this study  
Our series has some limitations. Scoring toxicity is complex and partly subjective to both the patient and 
clinician. The investigated symptom “rectal bleeding” is, though, an easy symptom to score objectively 
following the CTC score. The number of patients in the study is limited.  
Conclusion: 
The study found that CTV is a robust predictor for late rectal bleeding. None of the other investigated 
dosimetric or clinical parameters were significantly correlated with rectal bleeding. 
Conflict of interest: 
None to declare. 
Acknowledgements: 
The authors acknowledge The Lundbeck Foundation Center for Interventional Research in Radiation 
Oncology (CIRRO) and The Danish Council for Strategic Research. 
Research nurse Kirsten Steffensen is acknowledged for valuable practical help. 
Clinical and dosimetric parameters influencing on rectal bleeding after prostate radiotherapy 
Table 1. Patient characteristics. Range in parentheses. 
Patients (n) 143 
Median age (years) 70.3 (58-80) 
Pretreatment PSA (ng/ml) 15.0 (0.6-67) 
BMI 27.4 (19-24)
T-stage (n) 
T1 35 24.1%
T2 42 29.7%
T3 67 45.5%
T4   1    0.7% 
Gleason score (n) 
6   14   9.6% 
7 110 75.9%
8   11   7.6% 
9     9   6.2% 
10     1   0.7% 
Diabetes (yes/no) 21/124 14.5% 
Cardiac heart disease (yes/no) 90/55 62.1% 
Other chronic disease (yes/no) 56/89 38.6% 
Polyfarmacia (yes/no) 33/122 22.8% 
Nicotine (yes/no) 32/113 22.1% 
________________________________________________________________________________________________ 
Polyfarmacia defined as daily use of ≥5 drugs. Nicotine = smoking during radiotherapy and at time of survey 
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Table 2. Summary of the results. 
________________________________________________________________________________________________ 
          Univariate analysis            Multivariate analysis 
OR         CI(95%)     p-value                OR          CI(95%)        p-value          
Cardiac heart disease 0.79    0.39-1.60          0.52       
Diabetes 1.63    0.64-4.20          0.31 
Poly-farmacia  0.70    0.30-1.66          0.42       
Anti-coagulants  0.92    0.33-2.60          0.88       
ADT 0.88    0.47-1.65          0.70       
BMI 1.02    0.93-1.12          0.66       
Age* 0.94    0.87-1.01          0.08              0.91          0.84-0.99      0.03 
Smoking 0.39    0.19-1.03          0.06              0.41          0.14-1.19          0.10 
Pre-PSA*  1.01    0.98-1.04          0.54       
T-stage 1.40    0.91-2.17          0.13              1.47          0.89-2.43          0.13 
CTV* 1.01    1.00-1.03          0.01              1.01          1.00-1.03      0.03 
Ves. sem. irradiation 1.21    0.44-3.30          0.71       
Dmax* 1.52    0.89-2.58          0.13              1.00          0.66-1.47          0.95 
Dmean* 1.05    1.00-1.10          0.05              0.97          0.88-1.08          0.60 
Dmin2cc* 1.18    1.01-1.39          0.04              1.09          0.87-1.37          0.44 
V60Gy* 1.05    1.00-1.10          0.03              1.04          0.88-1.22          0.63 
V72Gy* 1.08    1.01-1.16        0.02              1.01          0.85-1.22          0.85 
OR= odds ratio.  
Poly-farmacia ≥5 different medications. 
ADT= androgen deprivation therapy.  
Ves. sem. = vesicula seminalis 
* Contineus variable OR per unit change
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Paper 3 
Five year follow-up using a prostate stent as fiducial in image guided 
radiotherapy of prostate cancer. 
Carl J, Sander L 
Acta Oncologica 2014 
The aim was to evaluate five year survival and morbidity data of the first 
patient cohort that underwent EBRT using image-guided radiotherapy 
(IGRT) of localized or locally advanced prostate cancer (PC) and the 
removable prostate stent as fiducial. 
Late genito-urinary (GU) and gastro-intestinal (GI) toxicities were scored 
using both the RTOG and the CTC-AE score. Urinary symptoms were also 
scored using the international prostate symptom score (IPSS).  
Overall survival, cancer specific survival and biochemical progression free 
survival were 85%, 96% and 80%, respectively. Late GU and GI RTOG 
scores>=2 were 5% and 0%. Comparing pretreatment and post-radiotherapy 
IPSS indicates that development in urinary symptoms after radiotherapy 
may be complex. 
To conclude the survival data were in accordance with recently published 
data. GU and GI toxicities at 5 year follow-up were low and comparable to 
the lowest toxicity rates reported in recent literature using modern RT like 
IMRT.  
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 Five-year follow-up using a prostate stent as ﬁ ducial in image-guided 
radiotherapy of prostate cancer 
 JESPER  CARL 1  &  LOTTE  SANDER 1,2 
 1 Department of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark and  2 Department of 
Urology, Aalborg University Hospital, Aalborg, Denmark 
 ABSTRACT 
 Purpose. To report results from the ﬁ ve-year follow-up on a previously reported study using image-guided radio-
therapy (IGRT) of localized or locally advanced prostate cancer (PC) and a removable prostate stent as ﬁ ducial. 
 Material and methods. Patients with local or locally advanced PC were treated using ﬁ ve-ﬁ eld 3D conformal radio-
therapy (3DRT). The clinical target volumes (CTV) were treated to 78 Gy in 39 fractions using daily on-line image 
guidance (IG). Late genito-urinary (GU) and gastro-intestinal (GI) toxicities were scored using the radiotherapy oncol-
ogy group (RTOG) score and the common toxicity score of adverse events (CTC) score. Urinary symptoms were also 
scored using the international prostate symptom score (IPSS). 
 Results. Median observation time was 5.4 year. Sixty-two of the 90 patients from the original study cohort were eli-
gible for toxicity assessment. Overall survival, cancer-speciﬁ c survival and biochemical freedom from failure were 85%, 
96% and 80%, respectively at ﬁ ve years after radiotherapy. Late toxicity GU and GI RTOG scores    2 were 5% and 
0%. Comparing pre- and post-radiotherapy IPSS scores indicate that development in urinary symptoms after radio-
therapy may be complex. 
 Conclusions. Prostate image-guided radiotherapy using a prostate stent demonstrated survival data comparable with 
recently published data. GU and GI toxicities at ﬁ ve-year follow-up were low and comparable to the lowest toxicity 
rates reported. These ﬁ ndings support that the precision of the prostate stent technique is at least as good as other tech-
niques. IPSS revealed a complex development in urinary symptoms after radiotherapy. 
 The use of ﬁ ducials in the prostate combined 
with image-guided radiotherapy (IGRT) has dem-
onstrated a signiﬁ cant reduction in positioning 
uncertainties during prostate radiotherapy, and 
consequently the potential to reduce setup margins 
and irradiated volume of normal tissue [1]. 
Reduced setup margins may be the main explana-
tion for the reduced radiation-induced genito-
urinary (GU) and gastro-intestinal (GI) late 
toxicity observed in several recent studies [2 – 4]. 
The reduction in setup margins may compromise 
treatment efﬁ ciency as suggested in some studies 
[5,6]. Several other studies, however, have reported 
unchanged or improved biochemical freedom from 
failure even with reduced setup margins [2 – 4]. 
Implanted gold markers (GM) has been the 
standard choice as ﬁ ducial in IGRT of prostate 
cancer [7]. The use of a nickle titanium removable 
prostate stent as ﬁ ducial for co-registration of plan-
ning computer tomography (CT) and magnetic 
resonance imaging (MRI) and subsequent IGRT 
treatment has been described in detail earlier 
[8 – 12]. Advantages of the prostate stent compared 
to gold markers were: 1) non-invasive; 2) remov-
able; 3) large 3D object; and 4) good signal i both 
CT and MR and thus well suited for MR CT 
co-registration of the prostate. This ﬁ ve-year 
follow-up of the clinical outcome following 
image-guided radiotherapy (IGRT) of localized 
or locally advanced prostate cancer (PC) repre-
sents a continuum of an ongoing process evaluat-
ing the removable prostate stent as ﬁ ducial. 
Acta Oncologica, 2014; Early Online: 1–6
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 Material and methods 
 Patients 
 The original cohort consisted of 90 patients with 
local and locally advanced prostate cancer. They were 
treated with radical radiotherapy at the University 
Hospital of Aalborg Denmark from March 2007 
until May 2009. The patient cohort is previously 
described in detail [11,12]. Exclusion from toxicity 
assessment was: biochemical failure, inability to read 
and understand the questionnaires in Danish and 
death. Biochemical failure was deﬁ ned as an eleva-
tion of prostate-speciﬁ c antigen (PSA) above nadir 
plus 2 ng/ml after radiotherapy. The study was in 
accordance with the standards of the Helsinki Dec-
laration of 1975, as revised in 2000. 
 Radiotherapy 
 The clinical target volume (CTV) was deﬁ ned as the 
prostate gland, or the prostate gland plus the proxi-
mal third part of the seminal vesicles in case of sem-
inal vesicle invasion. The CTV was outlined on CT 
using the co-registered MRI images. An isotropic 
CTV to PTV margin of 5 mm was used. External 
beam radiotherapy (EBRT) was given using a ﬁ ve-
ﬁ eld conformal plan (gantry angles at 9 ° , 90 ° , 140 ° , 
220 ° and 270 ° ). A CTV mean dose of 78 Gy in 39 
daily sessions was prescribed. Constraints to organs 
at risk (OAR) and further treatment details are given 
in [11]. The Brainlab ExacTrac TM system was used 
for daily on-line IG positioning matching the stent 
with a digital reconstructed radiogram (DRR) from 
the planning CT. OAR dose volume histograms were 
exported out of the treatment planning system (TPS) 
and dosimetry parameters calculated in Matlab TM . 
Patients with intermediate- and high risk according 
to the D ’ Amico classiﬁ cation received neo-adjuvant 
hormone therapy (AHT) with either LHRH ana-
logues or non-steroidal anti-androgens for three 
months before irradiation, during irradiation and for 
a limited period thereafter, usually for one year 
according to the recommendations in Denmark at 
time of treatment. 
 Toxicity assessment 
 All eligible men were invited for a yearly clinical visit 
at the department of urology. The visit included a 
blood sample for PSA measurement and toxicity 
assessment using the radiation therapy oncology late 
radiation morbidity scoring schema (RTOG) of GU 
and GI toxicity. At the ﬁ ve-year follow-up visit this 
was supplemented with a telephone interview using 
the national cancer institute common terminology 
criteria for adverse events (CTC-AE) version 4.0 
analogously to our previously reported three-year 
follow-up [12]. Urinary symptoms included fre-
quency, urgency, incontinence, dysuria, urinary 
retention and hematuria. Rectal symptoms included 
diarrhea, fecal incontinence, proctitis, rectal pain and 
rectal bleeding. 
 Furthermore urinary toxicity was evaluated using 
the validated international prostate symptom score 
(IPSS) patient questionnaire. Patients ﬁ lled in the 
questionnaire before prostate stent insertion, two 
weeks before start of the radiotherapy (baseline) and 
ﬁ ve years after end of radiotherapy. 
 Statistics 
 Survival data and biochemical freedom from failure 
data was calculated using the Kaplan-Meier method 
including all 90 patients from the original cohort. 
With regard to the cancer-speciﬁ c survival only 
patients that died from prostate cancer are counted. 
All other patients are censored at the date of their 
last visit or the date of eventual non-prostate cancer-
related death. Analogously, patients without bio-
chemical failure were censored at the date of last visit 
or the date of death without evidence of biochemical 
relapse. Five year RTOG and CTC scores were 
tested for correlation with Gleason score, T-stage, co-
morbidity, seminal vesicles irradiation, smoking, use 
of statins and polypharmacy using contingency tables 
and  χ 2 statistics. Five-year dichotomized RTOG and 
CTC scores (Grade    0 and Grade    0) were tested 
for dependency of continuous parameters, such as 
dosimetry parameters, age and prostate volume, 
using logistic regression. The dependency of RTOG 
and CTC toxicity scores on baseline IPSS was tested 
using ANOVA and t-test. Linear regression was used 
to test dependency of change from baseline at ﬁ ve 
year versus baseline IPSS. 
 Results 
 The median observation time was 5.4 years. Patient 
characteristics are shown in Table I. Of the original 
cohort of 90 patients, 10 patients died without bio-
chemical failure. Three patients died of prostate can-
cer, and a total of 15 patients had biochemical failure. 
Overall survival (OS), cancer-speciﬁ c survival (CSS) 
and biochemical freedom from failure (BFFF) with 
conﬁ dence interval limits are shown in Table II. The 
variation found concerning the high dose parameters 
(Dmax and V72Gy) are small (see Supplementary 
Table I, to be found online at http://informahealth
care.com/doi/abs/10.3109/0284186X.2014.987355). 
This is probably due to the standardized prescribed 
dose and the applied OAR dose constraints in the 
dose planning. Patient compliance with regard to 
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 Five-year follow-up using prostate stent in prostate cancer radiotherapy  3
toxicity assessment was 92% (57/62) for the RTOG 
score, 96% (60/62) for the CTC score and 92% 
(57/62) for the IPSS. A graphical representation 
showing peak toxicity scores are seen in Figure 1. 
The ﬁ gure also includes our previously reported 
three-year toxicity CTC scores in 73 patients for 
completeness and comparison of the RTOG scores 
at three and ﬁ ve years. No grade 3 or higher late 
toxicity was registered for either RTOG or CTC at 
any time. RTOG toxicity grades    2 were 5% and 0% 
for GU and GI, respectively. The CTC scores in 
Figure 1 demonstrate that the major adverse toxici-
ties at both three and ﬁ ve years were urinary fre-
quency and urgency with regard to GU toxicity 
(grade 2) in 13 – 15% of the patients and rectal bleed-
ing with regard to GI toxicity (only grade 1) in 18% 
of the patients. 
 Signiﬁ cantly higher RTOG GU toxicity at ﬁ ve 
years was found related to use of statins (p    0.005). 
Similar dependencies were observed for the CTC 
score at ﬁ ve years regarding urinary frequency 
(p    0.02) but not for urinary urgency. The CTC 
scores for both urinary frequency and urgency 
signiﬁ cantly correlated to polypharmacy (p    0.02 
and p    0.03, respectively). No signiﬁ cant dependen-
cies on OAR dosimetry parameters were found for 
either GU or GI toxicity scores, and no correlation 
of OAR dosimetry parameters with statin use or 
polypharmacy was found. 
 IPSS data including both pretreatment and ﬁ ve-
year follow-up results were available for 57 patients. 
A signiﬁ cant correlation between baseline IPSS and 
the RTOG GU score and CTC urinary frequency 
and urgency scores was found as shown in Table III. 
Table III also shows an overall statistically signiﬁ cant 
improvement in urinary symptoms at ﬁ ve-year 
follow-up compared to pretreatment based on 
the IPSS. 
 Figure 2 shows a plot of the change in IPSS at 
ﬁ ve-year follow-up from the baseline IPSS versus the 
baseline score. Linear regression showed a statisti-
cally signiﬁ cant lower IPSS change with increasing 
baseline IPSS after radiotherapy. Figure 2 demon-
strates that the change in IPSS versus baseline IPSS 
was signiﬁ cantly lower for patients with no toxicity 
symptoms (RTOG score    0) compared to patients 
with toxicity symptoms (RTOG score    0), but the 
decrease in change was similar for the two groups. 
 No signiﬁ cant correlations were found concern-
ing RTOG GI toxicity or CTC score for rectal 
bleeding. 
 Discussion 
 This paper reports the ﬁ ve-year follow-up results 
from the ﬁ rst clinical study using a prostate stent as 
ﬁ ducial during IGRT for prostate cancer. The sur-
vival data (OS: 85%, CSS 96% and BFFF 80%) are 
comparable with the data reported by the RTOG 
9406 study (78 Gy and a 3D conformal technique) 
[13]. They found OS at 85%, CSS at 99% and BFFF 
at 80%. However, the RTOG 9406 study had a lower 
fraction of high risk patients compared to our study 
(31% vs. 71.7% in our study cohort). Comparing 
survival data normally requires that the risk group 
frequencies are similar. 
 Data on BFFF for high risk patients have been 
comprehensively reviewed using highly standardized 
inclusion criteria ’ s in a recent study [14]. This review 
reported ﬁ ve-year BFFF in the range of 30 – 72% for 
high risk patients. Compared to this review our 
results are in the upper end of the reported range. 
Data from another Danish radiotherapy center has 
recently been reported [4]. This retrospective study 
compared 3D conformal with a 10 mm setup margin 
with IMRT combined with IGRT and a 5 mm setup 
margin for high risk patients. Only the three-year 
BFFF is reported; 86% for the 3D conformal and 
90.3% for the IMRT treatment. This corresponds 
 Table I. Patient characteristics of the 60 included patients in the 
ﬁ ve year toxicity scoring. 
Age (Mean (range) in years) * 68.5 (59 – 80)
T1 8 (13%)
T2 21 (35%)
T3 31 (52%)
Gleason score
6 10 (17%)
7 41 (68%)
8 5 (8%)
9 – 10 4 (7%)
PSA (Mean (range) in ng/ml) * * 15 (4 – 67)
Risk d’Amico classiﬁ cation
Low 3 (5%)
Intermediate 14 (23%)
High 43 (72%)
 * Age at study entry, ie. time of radiotherapy,  * * pre treatment
PSA 
 Table II. Five-year survival data for the original stent cohort of 
90 patients. 
Cum. 
Survival
Lo 95% 
CI
HR 95% 
CI
At risk 
5 yr
OS 85% 78% 93% 77
CSS 96% 92% 100%
BFFF Overall 80% 72% 89% 62
LR 100% NA NA 3
IR 85% 69% 100% 16
HR 77% 66% 88% 43
 OS: Overall survival 
 CSS: cancer speciﬁ c survival 
 BFFF: biochemical freedom from failure 
 LR: Low Risk, IR: Intermediate Risk HR: High Risk 
 CI: Conﬁ dence interval 
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4 J. Carl & L. Sander 
well to the previously reported three-year BFFF of 
89% for the cohort in this study [12]. Finally, a 
Canadian study also using a radiation dose of 79.8 
Gy and IG 3D conformal treatment with a margin 
of 10 mm demonstrated ﬁ ve-year BFFF of 77.9% for 
high risk patients comparable to the 77% found in 
this study [15]. To summarize the BFFF data using 
the prostate stent as ﬁ ducial are comparable with 
other studies using similar dose and IGRT tech-
niques. Consequently, it may be concluded that the 
 Table III. Baseline International prostate symptom score (IPSS) 
correlation with 5 year toxicity scores. 
RTOG 5y * N *
IPSS 
mean
IPSS 
StdDev ANOVA t-test
Grade 0 39 8.4 1.1 p    0.0006
Grade 1 12 12.8 1.9
Grade 2 3 23.7 3.8
CTC 5y urinary 
  frequency
Grade 0 39 8.3 1.0 p    0.00005
Grade 1 9 14.1 2.1
Grade 2 9 19.0 2.1
CTC 5y urinary 
  urgency
Grade 0 34 8.4 1.1 p    0.00003
Grade 1 16 11.5 1.6
Grade 2 7 21.4 2.4
All pre-treat 57 10.2 6.9
All 5 year 57 8.5 6.7 p    0.01
 * difference in N in this group is due to non overlapping of missing 
RTOG scores and IPSS questionairre. 
 Figure 1. The upper two panels show plot of the frequencies of RTOG scored toxicities in elegible pa-tients at each year in the five year 
follow-up period. The genito-urinary score frequencies to the left and the gastro-intestinal score frequencies to the right. The lower two panels 
analogously show the corresponding CTC scores at year three and five in the folllow-up period. RTOG and CTC scores are color coded grade    0: 
blue grade    1: brown grade    2: green. 
 Figure 2. Changes in IPSS at five year after radiotherapy from 
pretreatment IPSS plotted versus  pre-treatment IPSS. Linear 
regression lines and data points are shown for two groups: one 
group with RTOG toxicity score    0 (Blue), another group with 
RTOG toxicity score > 0 (Red). 
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 Five-year follow-up using prostate stent in prostate cancer radiotherapy  5
use of a prostate stent yields at least equal precision 
as gold markers. 
 The ﬁ ve-year RTOG GU and GI late toxicity 
grade    2 in this study were, respectively, at 5% and 
0%. These frequencies are in the low end compared 
to the ﬁ ndings published in a recent review, where 
scores grade    2 were ranging from 5.7% to 41% and 
4 – 33% for GU and GI toxicity, respectively [16]. The 
best studies applying intensity modulated radiother-
apy (IMRT) in this review had a ﬁ ve-year mean fre-
quency of RTOG score grade    2 of 15.5% (range 
7 – 28.3%) and 10% (range 4 – 21%), respectively, for 
GU and GI toxicity. Data from the recently published 
Danish study has demonstrated a signiﬁ cant improve-
ment in late toxicity at two-year observation time 
using IG-IMRT with a 5 mm setup margin as com-
pared to 3D conformal radiotherapy using a 10 mm 
setup margin [4]. They reported RTOG grade    2 
toxicity frequencies, respectively, for GU and GI for 
IG-IMRT of 29.7% and 5.8%, as compared to analo-
gous frequencies of 41.8% and 57.3% for 3D confor-
mal technique [4]. Consequently, the ﬁ ve-year RTOG 
grade    2 scores in the present study, applying a 3D 
conformal technique with 5 mm setup margin, were 
at least comparable to the toxicities for the IMRT 
technique reported from this other Danish center. The 
RTOG grade    2 toxicities in the present study are 
equivalent with the ﬁ ve-year RTOG grade    2 of 10% 
and 1.6% for GU and GI, respectively, reported in 
another recent study using IG-IMRT techniques [2]. 
Even though toxicity frequencies seem to lower using 
IG-IMRT techniques and small setup margins, these 
results are still controversial. Other studies have shown 
no effect of reducing the setup margin from 10 to 5 
mm and reported similar and excellent ﬁ ve-year 
RTOG grade    2 toxicities of 6.6 – 7% and 1.2 – 2.6% 
for GU and GI, respectively [17]. The exclusion of 
patients with BF from the toxicity analysis was to 
avoid interference in toxicity measures from either 
disease recurrence or salvage therapy. 
 To summarize the present study has demon-
strated very low GU and GI toxicity frequencies, but 
a caveat in the present study was a relatively small 
number of patients and the competing risks of death 
or BF, which may have led to underestimating ﬁ ve-
year toxicity frequencies. 
 The RTOG and CTC scores in this study gave 
consistent results with regard to hematuria and rectal 
bleeding. Only grade    1 toxicity was observed. An 
improvement in both hematuria and rectal bleeding 
from three to ﬁ ve years was observed as have been 
observed by others [18,19]. The complete clearance 
of hematuria from three to ﬁ ve years, however, seems 
unrealistic and is most probably an example of 
the competing risk of death. In general the CTC 
scores for urinary frequency and urgency were not 
consistent with the RTOG GU score at neither three 
nor ﬁ ve years. This inconsistency was probably due 
to increased frequency and urgency symptoms 
requiring  α -blocker medications, which scores as 
grade 2 in CTC only. 
 Unexpectedly, the use of statin signiﬁ cantly cor-
related with more adverse urinary toxicities estimated 
on both RTOG GU scores and CTC scores at ﬁ ve 
years. The observation of increased urinary toxicity 
seems, most likely, to be a confounder effect, as 
the use of statin also correlated signiﬁ cantly to pre-
treatment urinary toxicity estimated on IPSS and 
poly-pharmacy. Unfortunately, no pre-treatment 
scores existed for either RTOG or CTC in the present 
study. However, a pre-treatment (baseline) IPSS value 
has been recorded for most patients in the original 
cohort [11]. The ﬁ ve-year CTC and RTOG toxicity 
scores of urinary frequency and urge were signiﬁ cantly 
related to the baseline IPSS, again indicating that pre-
treatment morbidity could have inﬂ uenced the scor-
ing at ﬁ ve-year follow-up. Actually, this study 
demonstrated that a signiﬁ cant overall improvement 
in IPSS urinary symptoms occurred at the ﬁ ve-year 
follow-up as compared to the pre-treatment IPSS 
level. Such an effect has been described by others 
[20]. Furthermore, change in IPSS at ﬁ ve years com-
pared to pre-treatment levels demonstrated improve-
ment in urinary symptoms with increasing 
pre-treatment IPSS as demonstrated by the regression 
line in Figure 2. This improvement was counteracted 
by manifest radiotherapy toxicity as may be seen by 
the upward shift of the regression line for patients with 
a RTOG toxicity score. Consequently, the urinary 
symptoms observed in this study indicate that devel-
opment in urinary symptoms after radiotherapy may 
be more complex as counter acting effects after radio-
therapy may occur over time. Such effect may com-
plicate things when urinary late toxicity from different 
studies are compared. It may also explain why cor-
relation of urinary toxicity to radiation dose may often 
be elusive. We recommend that future monitoring 
of urinary toxicity should include pre-treatment 
and follow-up IPSS in patients treated for localized 
prostate cancer with modern radiotherapy. 
 Conclusion 
 A new technique using a prostate stent as ﬁ ducial 
demonstrated survival data comparable with other 
published data. Genito-urinary and gastro-intestinal 
toxicities at ﬁ ve-year follow-up were low and compa-
rable to lowest reported toxicities in the literature. 
These ﬁ ndings support that the precision of the pros-
tate stent technique is at least as good as other tech-
niques. IPSS revealed a complex development in 
urinary symptoms after radiotherapy. 
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MR or CT for target volume delineation in radical prostate cancer 
radiotherapy – five year toxicity and Quality of life outcomes 
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MR target delineation reduces CTV compared to CT delineation in prostate 
cancer radiotherapy. The potential impact in a clinical setting on toxicity 
and QoL is not yet thoroughly investigated. The study compared long-term 
toxicity and QoL in two groups of patients using MR or CT target 
delineation in prostate cancer radiotherapy 5 years after therapy.  The 
treatments were performed with the same radiation dose and PTV margins. 
Potential correlations with clinical and dosimetric parameters were also 
investigated. 120 patients were eligible for toxicity and QoL assessment. 
For the entire cohort overall survival 5 year overall survival was 84% and 
biochemical freedom from failure was 83%. The mean CTV was 18% larger 
in the CT group compared to the MR group. Five year toxicities were in 
general few and mild; no grade 3 or 4 toxicity was found. No difference in 
overall urinary or rectal toxicity was found despite the minor CTV volume 
in the MR group. No difference in global health was seen either.  EORTC 
bowel score were significantly lower in the MR group. 
 The mean rectal dose and high rectal dose volumes were significantly 
smaller in the MR group compared to the CT group. V72 was correlated to 
EORTC bowel score and overall rectal toxicity. 
LONG-TERM FOLLOW-UP AFTER MODERN RADICAL PROSTATE CANCER RADIOTHERAPY 
78
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Abstract: 
Background and purpose 
MR target delineation reduces clinical target volume (CTV) compared to CT delineation in prostate 
cancer (PC) radiotherapy. Potential impact on long-term toxicity and Quality of Life (QoL) is not yet 
thoroughly investigated. This study compares toxicity and QoL using CT or MR delineation in PC 
radiotherapy. 
Material and Methods 
Patients were treated with high dose image guided radiotherapy (78Gy). Urinary and rectal toxicity 
(CTC-AE) and Quality of Life (EORTC) was assessed 5 years after radiotherapy. Potential 
correlations with clinical and dosimetric parameters were investigated.  
Results 
Of the original cohort of 202 patients 120 patients had toxicity and QoL assessed. For the entire 
patient cohort, five year overall survival was 84% and biochemical freedom from failure was 83%. 
The mean CTV was 18% larger in the CT group compared to MR. The mean rectal dose and high 
rectal dose volumes were significantly smaller in the MR group compared to the CT group. EORTC 
bowel score were significantly lower in the MR group.  
Conclusions 
MR delineation leads to a significantly reduced CTV and to lower rectal high dose and mean dose 
volumes. Late toxicities were in general few and mild in both groups. No significant differences 
were found. Significant less EORTC bowel symptoms were observed using MR delineation.  
Introduction 
External-beam radiotherapy (EBRT) is a well-established treatment in patients with prostate cancer 
(PC). Improved biochemical control following dose escalation up to 74-78Gy have been shown in 
several randomized studies, but at the cost of an increase in the treatment related late urinary and 
rectal toxicities (1-3). Day to day changes in patient position and variations in prostate position 
during the course of radiation are known sources of treatment errors. Modern radiation technology 
like the use of fiducials markers and image guided radiotherapy (IGRT) reduce these uncertainties 
and have resulted in decreased margins from clinical target volume (CTV) to planning target 
volume (PTV), allowing the delivery of higher radiation doses with lower frequency of late rectal 
and urinary toxicities (4-6). Today, the most used method is implanted gold markers (GM) 
combined with treatment planning on computed tomography. It is known, though, that this 
method leads to an overestimation of the prostate volume. Studies examining computed 
tomography (CT) prostate delineation compared to MR delineation has demonstrated volumes 30-
40% larger following CT-delineation (7-9). Consequently the irradiated volume of normal tissue, 
such as urinary bladder and rectum may be smaller using MR and may improve treatment related 
toxicity. This could potentially, allow for further dose escalation. However, MR delineation is not 
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easily accessible in all radiotherapy departments, it is potentially expensive and time consuming. It 
is therefore of significant relevance to current practice to thoroughly evaluate long term follow-up 
comparing these two target delineation modalities. Consequently, the aim of the present study 
was to evaluate the five year toxicity and quality of life (QoL) outcomes after high dose 
radiotherapy in two groups of patients using either MR or CT for clinical target delineation.  
Material and methods 
Patients 
The cohort included patients with localized or locally advanced PC (T1-T3N0M0) treated with 
curatively intended radiotherapy between March 2007 and May 2009 at the department of 
Oncology, Aalborg University Hospital. During this period, a group of 100 patients participated 
voluntarily in a fase 3 trail evaluating a Ni-TI stent for MR-CT co-registration and as fiducial 
marker. Ninety patients completed the treatment in the trail. Another consecutive group of 102 
prostate cancer patients had standard planning CT and gold markers as fiducials within the chosen 
period. The patients were identified through searches in the patient radiation databases at the 
department of Oncology, Aalborg University Hospital. Reasons for exclusion from the toxicity and 
QoL assessment were inability to read and understand the questionnaires in Danish, death and 
biochemical failure (defined as nadir +2). The latter to avoid interference in toxicity measures from 
either disease recurrence or salvage therapy. Information on patient clinical data, co-morbidity, 
survival and biochemical failure was extracted from hospital patient records. The study was 
approved by the Regional Committee for Medical Research Ethics. 
Radiotherapy treatment: 
Patients were stratified into risk groups according to the d’Amico risk classification (10). Patients 
with intermediate or high risk received neo-adjuvant endocrine treatment with either LHRH 
analogues or non-steroidal anti-androgen for 3 month before irradiation. RT treatment details are 
described in (11). The CTV was defined as the prostate gland. In case of seminal vesicle (SV) 
invasion on biopsy, Partin tables > 10% risk of invasion or T3 disease, the CTV included the 
proximal third part of the SV. The external contours of organs at risk were outlined on the planning 
CT (rectum and bladder). The rectum was defined from the anal sphincter to beginning of the 
sigmoid. A PTV was created using an isotropic PTV to CTV margin of 5mm. Treatment planning 
was based on a 3D conformal technique with five conformal fields. A total of 78Gy was given in 39 
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fractions five days a week using the inserted fiducials for daily image guidance. The following 
constraints were used for normal tissue: Rectum V70<=25%, V60<=50%, dorsal part of rectum 
Dmax< 65 Gy and for the bladder V70<=35% and V60<=50%.  
 
Toxicity assessment: 
Toxicity and QoL was assessed for the individual patient five years after completion of his RT. 
Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTC-AE) version 4.0. Urinary symptoms included haematuria, frequency, urinary 
incontinence, retention, dysuria and urgency. Rectal symptoms included diarrhea, fecal 
incontinence, proctitis, rectal pain and rectal bleeding. With regard to patient reported outcome the 
questionnaires used were the global life questionnaire (C30) and the prostate module (PR25) from 
the European Organization for Research and Treatment of Cancer (EORTC). Chosen outcome 
measures from the C30 questionnaire were the different functional scales, the global health score 
and the symptom scales “pain” and “fatigue”. From the PR25 the chosen outcome scales were the 
Urinary symptoms (eight items), bowel symptoms (four items) and sexual activity (two items). 
 
Statistics: 
Overall survival (OS) and biochemical freedom from failure (BFFF) were calculated using the 
Kaplan-Meier method. Patient characteristic and late toxicity score comparisons were made 
between the CT and MR groups, using the t-test or Mann-Whitney test for continuous variables 
and χ2 or Fisher’s exact test for categorical variables. The CT group was used as a reference when 
comparing the two treatment groups. Scores for patient-reported outcomes in terms of the EORTC 
QoL questionnaires were analysed according to the EORTC scoring manual (12;13). For ease of 
statistical interpretation, all scale and item scores were linearly transformed to a scale from 0 to 
100. For the functional functional scales and the global quality-of-life scale, a high score represents 
a good level of functioning. For the symptom scales and items, a high score corresponds to more 
severe symptoms. Missing data was handled as recommended by the EORTC. Possible correlations 
between the different outcomes were tested by univariate (UVA) and eventually multivariate 
(MVA) linear or logistic regression models. The toxicity data were transformed into binary values 
either grade 0 or ≥1 before doing eventual logistic regression analysis. P-values are two-sided and 
statistical significance was set at 5%. The data were analysed using STATA v11 (Stata statistical 
software version 11; Stata Corporation).  
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Results 
Patient flow is shown in Figure 1. Thirteen of the 202 patients came from other regions or 
countries and had no follow-up at all in the department. Characteristics of the remaining 189 
patients are shown in table I. The two groups were comparable with respect to the clinical risk 
factors: Gleason score, pre-treatment PSA, inclusion of SV in the CTV, age, smoking and 
haemorrhoids. Significantly higher T-stages and risk group classifications were present in the MR 
group compared to the CT group. There was no difference observed between the two groups 
considering co-morbidity: diabetes, cardio-vascular disease, chronic obstructive pulmonary disease 
(COPD), and other chronic diseases (data not shown), neither in the use of medications.  
The size of the groups and number of events were too small to give statistical power to compare 
survival data between the two groups. For the total cohort overall survival was 0.84 and the 
biochemical failure free survival data was 0.83 with a median observation after RT of 5.4 years.  
The mean CTV volumes were 42 cm3 versus 50 cm3 for the MR and CT group, respectively, and 
thus 18% larger in the CT group compared to the MR group.  
120 patients were eligible for the toxicity and QoL scoring. One of these patients accepted toxicity 
assessment but did not fill out QoL questionnaires because of end stage ENT cancer.  Another 
patient filled out the PR25 but chose not to fill out the C30 because of severe COPD and daily 
oxygen requirement. 
In general, the late side effects were few and mild in both groups. No grade 3 or 4 toxicity was 
registered. The 5 year rectal and urinary toxicity scores are shown in table II. No difference in 
overall rectal or urinary toxicity (table III) between the groups were found (p=0.84 and p=0.16, 
respectively). Overall rectal toxicity was correlated to v72 (p=0.02) and logCTV (p=0.03) doing a 
UVA logistic regression analysis. Concerning the rectal symptoms the most frequent finding was 
rectal bleeding grade 1 in both groups. Rectal bleeding was correlated to logCVT (p=0.01), v72Gy 
(p= 0.01) and inclusion of SV in the CTV (p=0.02) in a UVA logistic regression analysis. No 
significant difference was found in the incidence of the different rectal symptoms between the 
groups, though diarrhoea showed a tendency of being less frequent in the MR group with 
borderline significance (p=0.06). There was no influence of age, T-stage, Gleason score, pre-
treatment PSA, CTV, seminal vesicles irradiation or the dosimetric parameters on the development 
of the rectal symptoms except as mentioned above.  
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Regarding urinary toxicity patients in both groups were mainly bothered with increased urinary 
frequency and urgency grade 1 and 2. Toxicities were similar in the two groups, though with 
borderline significance concerning haematuria and urinary frequency, both showing the trend to be 
less frequent in the MR group (p=0.06 for both). There was no influence of age, T-stage, Gleason 
score, pretreatment PSA, CTV, or any of the dosimetric data on the development of urinary 
toxicity. 
EORTC QoL results are presented in table IV. In general, they showed a high level of functioning 
and a low level of symptoms in both groups. The bowel symptom score differed significantly 
between the 2 groups (p=0.01) being lower in the MR group. The cognitive score was also 
significantly different otherwise the groups had similar QoL outcomes. No correlation was found 
between the QoL scores and age.  
The EORTC urinary score correlated significantly with the overall urinary toxicity score likewise the 
QoL bowel score was significantly correlated with the overall rectal toxicity score ( p=0.001 for 
both).  
Table V show the dose characteristics for the OAR: rectum and bladder. No difference in rectal or 
bladder volume was observed between the two groups. But rectal mean dose and high dose 
volumes (v50gy, v60gy and v72gy) were significantly lower in the MR group compared to the CT 
group, in accordance with the observed difference in CTV. Analogously, lower mean and high dose 
volumes were observed for the bladder in the MR group, although not statistically significant.  
Discussion 
This study aimed at comparing toxicity and Quality of Life outcomes after radical radiotherapy for 
localized or locally advanced prostate cancer in two groups using MR or CT imaging for CTV 
delineation. The average CTV was 18% larger in the group with CT delineation compared to MR 
delineation. Possible explanations of the difference in the present study could be that the 
distribution of the true prostate volumes was different between the MR and CT group. Different 
papers have demonstrated that there is an association between high grade cancers and a smaller 
prostate volume (14;15). This could be a possible confounder in that the MR group had a 
significantly higher number of high risk patients. The d’Amico risk group classification consists of 
the three outcomes:  Gleason score, PSA level and T-stage. In this study, there was no significant 
difference in the matter of the Gleason-score, thus the potential confounder can probably be 
neglected in this case. Neoadjuvant hormonal treatment is also known to reduce prostate size, 
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however the distribution between the groups were equal in the present study (p=0.41). The 18% 
difference between CT and MR delineation was considerably less than previously reported 
difference of 30-40% (7-9;16). A possible explication of the reduced CTV difference compared to 
other studies could be that the regular use of MR in our centre may have impacted the physicians 
experience in outlining the prostate on CT (8), and thus reduced the difference between the CT 
and MR group. The similar toxicities between the two groups found in the study may also be a 
result of this. 
The size of the groups and number of events were too small to give statistical power to compare 
survival data between the two groups. But the OS and BFFS for the total patient population in the 
present study were comparable to newly published results regarding high dose 3D conformal EBRT 
(17;18).  
Late urinary and rectal toxicity 5 years after radiotherapy were mainly grade 0 or 1 in the present 
study. Maximum toxicity score was grade 2, which was observed in 10% and <1% of the patients 
concerning the urinary and rectal toxicity, respectively. The values are low compared to the results 
published in a recent review (19). In this review the 5 year late toxicity grade>=2 was ranging 
from 6-41% and 4-33% concerning urinary and rectal toxicity, respectively. The lowest toxicity 
rates found in the review were in studies applying IMRT. These studies had a mean frequency of 
grade>=2 toxicity of 15.5% (range 7-28.3%) regarding the urinary toxicity and 10% (range 4-
21%) regarding the rectal toxicity.  
In the present study, no significant difference in 5 year late urinary toxicity was found between the 
MR and CT groups. Haematuria and frequency showed the tendency to be more pronounced in the 
CT group (both p=0.06). This could be an effect from the use of MR for prostate delineation, as 
the bladder wall may be excluded from the CTV on MR, this is not possible using CT. No difference 
between the groups relating to the dosimetric data to the bladder was found. There was a trend 
towards a smaller bladder high dose volume in the MR group compared to the CT group, however 
not statistically significant. With the relatively small number of patients in mind, the observed 
tendency could be due to the competing risk of death before 5 years.  
With regard to the rectal toxicity no significant differences between the two groups were found. A 
trend towards less diarrhoea was observed in the MR group compared to the CT group (p=0.06). 
The rectal high dose volume (v72gy) was found to be significantly smaller in the MR group 
compared to the CT group. Both logCTV and v72gy were correlated with rectal bleeding and 
overall rectal toxicity. But no significant difference in rectal toxicity was observed between the 
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groups. The missing difference in rectal bleeding may be explained by the fact that the difference 
in CTV between the MR and CT group was small, and the average v72gy values were low in both 
groups, in accordance with the observed low frequency of rectal bleeding. Finally the low toxicity 
frequencies combined with the limited number of patients in the study may have limited the 
detection of significant differences.  
The QoL assessment showed no significant differences between the two groups except for 
cognitive functioning and bowel symptoms, where the MR group had higher cognitive functioning 
and lower bowel symptom score. Age and co-morbidities, that could otherwise influence QoL, did 
not differ between the groups. OoL can be affected both by the disease as well as the treatment. 
The risk of disease recurrence was higher in the MR group because of the significantly higher 
number of high risk patients. This could possibly influence QoL, but without baseline scores from 
both groups no reliable analysis could be done. 
The EORTC bowel symptom score was significantly smaller in the MR group compared to the CT 
group, though only defined as a minor difference according to Osoba (20) and may not be 
clinically relevant. This observed difference could be due to pre-treatment differences between the 
two groups. However, the EORTC bowel symptom score was highly correlated to overall rectal 
toxicity. The findings of a reduced logCTV and v72 in the MR group and their correlation with 
overall rectal toxicity suggest that a difference in late radiation toxicity is a likely explanation for 
the lower bowel symptom score observed in the MR group compared to the CT group.  
The difference found relating to cognitive functioning is not interpreted as a result of the different 
treatment setups, but may be a selection bias in that patients with high cognitive functioning may 
be more likely to accept participation in medical trails. This can explain the higher cognitive 
functioning in the MR group. 
Urinary toxicities seem to be the most frequent cause of treatment related symptoms in the era of 
modern radiotherapy and should be part of future work. No significant data was found in this 
study, that MR delineation compared to CT delineation reduces urinary toxicity. Urethra sparing 
has so far been considered controversial because of concerns for under dosage of the peri-urethral 
tissue.  A recent theoretical study using MR delineation and the Ni-TI stent as fiducial, combined 
with IMRT demonstrated that lower urinary toxicities may be possible without compromising 
tumour control (21). 
A delicate balance exists aiming for both maximum accuracy (high BFFS) and maximum margin 
reduction (low toxicity).  The extent of microscopic disease remains uncertain because of limits in 
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imaging modalities.  Recent reports of decrease in BFFS have been published (22-24). The 
potential benefit of an inaccurate CTV could be that it accounts for errors that we would normally 
consider part of the PTV expansion. The development in modern imaging technology will hopefully 
help solving this problem.   
Limitations in this study are as mentioned before a small number of both patients and events, this 
limits the statistical power. Baseline assessments before RT would be preferable to better evaluate 
both toxicity and QoL. This may be particularly relevant in an elderly patient population like 
prostate cancer patients as some symptoms may be due to undetected co-morbidity progression. 
The utilisation of MR in patient work-up process is potentially expensive, time consuming and not 
always accessible in all radiotherapy departments. It may be discussed whether the differences in 
bladder and rectal toxicity between the MR and CT group observed in this study are clinically 
relevant.  The effect of MR delineation will require further confirmation with future prospective 
studies on more patients and longer follow-up to evaluate the clinical relevance in term of possible 
toxicity reduction and gain in QoL. 
Conclusions 
The clinical target volume and the rectal high dose volume (v72Gy) were significantly smaller in 
the MR group compared to the CT group. Significantly less EORTC bowel symptoms was observed 
in the MR group compared to the CT group. No difference in urinary toxicities was observed 
between the MR and CT group. 
Conflict of interest 
None to declare. 
Acknowledgement 
The study was supported by the Lundbeck Foundation Center for Interventional Research in 
Radiation Oncology (CIRRO). Research nurses Kirsten Steffensen and Britt Stiholt are 
acknowledged for practical help. 
MR versus CT clinical target delineation   Sander et al. 
 
Side 10 af 12 
 
Reference List 
 
 (1)  Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. 
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate 
cancer. Int J Radiat Oncol Biol Phys 2008 January 1;70(1):67-74. 
 (2)  Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A. Long-term 
results of conformal radiotherapy for prostate cancer: impact of dose escalation on 
biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat 
Oncol Biol Phys 2008 July 15;71(4):1028-33. 
 (3)  Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, 
Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens 
RJ, Syndikus I, Parmar MK. Escalated-dose versus standard-dose conformal radiotherapy 
in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet 
Oncol 2007 June;8(6):475-87. 
 (4)  Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, 
Rosewall T, Warde PR, Catton CN. Image guided dose escalated prostate radiotherapy: 
still room to improve. Radiat Oncol 2009;4:50. 
 (5)  Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, 
Lovelock M, Hunt M. Improved clinical outcomes with high-dose image guided radiotherapy 
compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J 
Radiat Oncol Biol Phys 2012 September 1;84(1):125-9. 
 (6)  Kok D, Gill S, Bressel M, Byrne K, Kron T, Fox C, Duchesne G, Tai KH, Foroudi F. Late 
toxicity and biochemical control in 554 prostate cancer patients treated with and without 
dose escalated image guided radiotherapy. Radiother Oncol 2013 May;107(2):140-6. 
 (7)  Hentschel B, Oehler W, Strauss D, Ulrich A, Malich A. Definition of the CTV prostate in CT 
and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther 
Onkol 2011 March;187(3):183-90. 
 (8)  McLaughlin PW, Evans C, Feng M, Narayana V. Radiographic and anatomic basis for 
prostate contouring errors and methods to improve prostate contouring accuracy. Int J 
Radiat Oncol Biol Phys 2010 February 1;76(2):369-78. 
 (9)  Rasch C, Barillot I, Remeijer P, Touw A, van HM, Lebesque JV. Definition of the prostate in 
CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999 January 1;43(1):57-
66. 
 (10)  D'Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A. The use of clinical 
parameters in an interactive statistical package to predict pathological features associated 
with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health 
Care 1993 October;1(4):219-22. 
 (11)  Sander L, Langkilde NC, Holmberg M, Carl J. MRI target delineation may reduce long-term 
toxicity after prostate radiotherapy. Acta Oncol 2014 June;53(6):809-14. 
MR versus CT clinical target delineation  Sander et al. 
Side 11 af 12 
(12)  van AG, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, 
Thalmann G, Akdas A, D'Haese S, Aaronson NK. An international field study of the EORTC 
QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with 
prostate cancer. Eur J Cancer 2008 November;44(16):2418-24. 
(13)  Fayers P. The EORTC QLQ-C30 scoring manual. 3rd edition.  2001.  European 
Organization for Research and treatment in Cancer.  
Ref Type: Internet Communication 
(14)  Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, 
Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and 
adverse prostate cancer features: fact not artifact. Eur J Cancer 2007 
December;43(18):2669-77. 
 (15)  Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, 
Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Jr., Barocas DA. Smaller prostate 
size predicts high grade prostate cancer at final pathology. J Urol 2010 
September;184(3):930-7. 
(16)  Gao Z, Wilkins D, Eapen L, Morash C, Wassef Y, Gerig L. A study of prostate delineation 
referenced against a gold standard created from the visible human data. Radiother Oncol 
2007 November;85(2):239-46. 
(17)  Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, 
Valicenti RK, Cox JD. Clinical outcome of patients treated with 3D conformal radiation 
therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012 
July 1;83(3):e363-e370. 
(18)  Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, 
Rosewall T, Warde PR, Catton CN. Image guided dose escalated prostate radiotherapy: 
still room to improve. Radiat Oncol 2009;4:50. 
(19)  Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for 
prostate cancer. Can J Urol 2012 August;19(4):6373-80. 
(20)  Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in 
health-related quality-of-life scores. J Clin Oncol 1998 January;16(1):139-44. 
(21)  Thomsen JB, Arp DT, Carl J. Urethra sparing - potential of combined Nickel-Titanium stent 
and intensity modulated radiation therapy in prostate cancer. Radiother Oncol 2012 
May;103(2):256-60. 
(22)  Heemsbergen WD, Hoogeman MS, Witte MG, Peeters ST, Incrocci L, Lebesque JV. 
Increased risk of biochemical and clinical failure for prostate patients with a large rectum at 
radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat 
Oncol Biol Phys 2007 April 1;67(5):1418-24. 
(23)  Witte MG, Heemsbergen WD, Bohoslavsky R, Pos FJ, Al-Mamgani A, Lebesque JV, van 
HM. Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy 
vs. 78 Gy. Int J Radiat Oncol Biol Phys 2010 May 1;77(1):131-8. 
MR versus CT clinical target delineation  Sander et al. 
Side 12 af 12 
(24)  Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for prostate cancer: 
increased biochemical failure in patients with distended rectum on the planning computed 
tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys 
2009 June 1;74(2):388-91. 
CHAPTER 8. DISCUSSION 
91 
CHAPTER 8. DISCUSSION 
The following discussion will relate to the most central aspects of this PhD 
thesis evaluating a new treatment modality using MRI target planning and a 
Ni-Ti prostate stent as fiducial marker for both MR-CT co-registration and 
IGRT. The background for the projects was the search of better target 
planning before therapy and better visualization during therapy; ultimately 
to try to optimize treatment results but minimize treatment related side-
effects. More specific discussions of the findings of the studies can be found 
in the discussion sections of the corresponding papers I-IV. 
Toxicity following curative treatments of any cancer is a crucial issue and 
toxicity reduction is a general ambition irrespective of the treatment 
modality. With regard to PCa patients the issue becomes extremely relevant 
since the group of patients that are offered the curative treatments, most 
often have no symptoms of their cancer disease at all. The number needed to 
treat is high with regard to prostate cancer. In the case of PSA screening, 
one reference study reported that 48 additional cases of prostate cancer 
would need to be treated to prevent one death from prostate cancer (123). 
Furthermore, the indolent nature of the disease affecting mostly elderly men 
comes to that many of the PCa patients will die of other causes but with the 
potential side-effects following the curative treatment. 
The theoretical advantage of MRI delineation would be a reduced and a 
more accurate CTV. We found a significant difference in CTV between the 
group with CT delineation compared to MRI delineation with 18% larger 
volumes in the CT group (5 year results). Possible explanations of the 
difference could be that the distribution of the true prostate volumes was 
different between the MR and CT group. Different papers have 
demonstrated that there is an association between high grade cancers and a 
smaller prostate volume (124;125). This could be a possible confounder in 
that the MR group had a significantly higher number of high risk patients. 
The d’Amico risk group classification consists of the three outcomes:  
Gleason score, PSA level and T-stage. In this study, there was no significant 
difference in the matter of the Gleason-score, thus the potential confounder 
can probably be neglected in this case. Neoadjuvant hormonal treatment is 
also known to reduce prostate size, however the distribution between the 
MR and CT groups were equal (p=0.41). 
The 18% volume difference between CT and MRI delineation was 
considerably less than previously reported difference of 30-40% (53-56). 
The contouring variation seen using MRI is lower than with CT because of 
the superior distinction of the prostate from adjacent structures on MRI. 
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However, with training, these structures can many times be recognized on 
CT scans as well (55). The regular use of MRI in our centre may have 
impacted the physicians experience in outlining the prostate on CT, and thus 
reduced the difference between the two groups. However, the results still 
showed that a significant reduction in CTV after MRI delineation compared 
to CT delineation is feasible in clinical practice. 
The 5 year follow-up using the RT technique based on the Ni Ti stent 
demonstrated in paper III that survival rates (OS: 85%, BFFS: 80%) were 
comparable with the recent RTOG study 9406 (86) where OS: 85% and 
BFFS: 80% were found in the matter of 3D-CRT (78Gy) treatment. Even if 
the RTOG 9406 study had a lower fraction of high risk patients compared to 
our study cohort (31% vs. 72%). The 5 year RTOG toxicity scores 2≥ were 
very low (GU toxicity 5% and GI toxicity 0%). A recent review published 
toxicity scores ≥2 ranging from 5.7-41% and 4-33% for GU and GI toxicity, 
respectively (126). A study using IMRT techniques have reported 5 year 
RTOG ≥2 scores of 10 and 1.6% for GU and GI, respectively (91). We 
conclude that the RT technique based on the Ni-Ti stent as marker during 
IGRT for PCa yields a precision at least as good as other techniques. 
The size of the two groups and number of events were too small to give 
statistical power to compare survival data between the two groups. But 5 
year OS and BFFS for the total patient population were comparable to 
newly published results regarding high dose 3D conformal EBRT (86;127).  
The results of the 3 and 5 year toxicity assessments after either MRI or CT 
delineation in paper I and IV showed in both assessments very low CTC-AE 
toxicity rates. As mentioned, the regular use of MRI in our centre may have 
impacted the physicians experience in outlining the prostate on CT. This 
may have influenced the quite similar toxicities. No difference in overall 
rectal or urinary toxicity was found at 3 or 5 years. At 3 years follow-up less 
urinary frequency and urinary retention was found in the MR group, at 5 
years this significant difference had disappeared but less diarrhoea was then 
found in the MR group. The CTV was at 3 years found correlated to both 
rectal bleeding and overall rectal toxicity, at 5 years the correlation with 
overall rectal toxicity disappeared but a correlation between rectal bleeding 
and both CVT and v72Gy was found. The toxicity levels were at both 
assessments comparable with data from the literature (91;126;128). 
Urinary toxicities seem to be the most frequent cause of treatment related 
symptoms in the era of modern radiotherapy as confirmed in paper I and IV. 
No significant data was found in these studies, that MR delineation 
compared to CT delineation reduces urinary toxicity in long-term follow-up. 
Urethra sparing has so far been considered controversial because of 
concerns for under dosage of the peri-urethral tissue.  A recent theoretical 
study using MRI delineation and the Ni-TI stent as fiducial, combined with 
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IMRT demonstrated that lower urinary toxicities may be possible without 
compromising tumour control (129). 
The QoL assessment at 5 year follow-up showed no significant differences 
between the two groups except for cognitive functioning and bowel 
symptoms. The MR group had higher cognitive functioning and lower 
bowel symptom score. Age and co-morbidities, that could otherwise 
influence QoL, did not differ between the groups. OoL can be affected both 
by the disease as well as the treatment. The risk of disease recurrence was 
higher in the MR group because of the significantly higher number of high 
risk patients. This could possibly influence QoL, but without baseline scores 
from both groups no reliable analysis could be done. 
The EORTC bowel symptom score was significantly smaller in the MR 
group compared to the CT group, though only defined as a minor difference 
according to Osoba (130) and may not be clinically relevant. In our study 
the difference in EORTC bowel symptom score correlated well with the 
observed lower frequency of diarrhoea in the MR group. These observations 
could be due to pre-treatment differences between the two groups. However 
the EORTC bowel symptom score was also correlated to overall rectal 
toxicity and furthermore to the rectal high dose volume (v72gy). These 
findings suggest that a difference in late radiation toxicity is a likely 
explanation for the lower bowel symptom score observed in the MR group 
compared to the CT group. The difference found relating to cognitive 
functioning is not interpreted as a result of the different treatment setups, 
but may be a selection bias in that patients with high cognitive functioning 
may be more likely to accept participation in medical trails. This can 
explain the higher cognitive functioning in the MR group. 
No difference between the groups relating to the dosimetric data to the 
bladder was found. There was a trend towards a smaller bladder high dose 
volume in the MR group, however not statistically significant.  
The dosimetic data to the rectum differed between the two groups in the 
matter of high dose (v50, v60 and v72Gy) as well as rectal mean dose. All 
of them significantly lower in the MR group. The logCTV and v72gy were 
correlated with rectal bleeding at 5 years (p=0.05 and p=0.01, respectively). 
But no significant difference in rectal bleeding toxicity score or any of the 
other chosen rectal symptoms was observed (except diarrhoea as 
mentioned). The missing difference in rectal toxicity may be explained by 
the fact that the difference in CTV between the MR and CT group was 
small, and the average v72gy values were low in both groups, in accordance 
with the observed low frequency of rectal bleeding. A larger patient 
population would probably be required to demonstrate a difference in rectal 
toxicity between the groups. The strong correlation found in paper II 
between CTV and rectal bleeding and the finding of a smaller CTV in the 
LONG-TERM FOLLOW-UP AFTER MODERN RADICAL PROSTATE CANCER RADIOTHERAPY 
94
 
MR group in this study sustain this theory. The prostate cancer dose 
escalation trial, RTOG 9406 also found that larger PTVs were associated 
with increased rectal toxicity (131). Several other studies have evaluated 
rectal dose-volume histograms and have found consistent results on the 
dose-volume effect on the probability of developing rectal bleeding (132-
135). Both the absolute and the percentage of rectal volume receiving the 
highest doses (>60Gy) are correlated with rectal bleeding (111). As the 
CTV increases a larger volume of the rectum is at risk of high dose 
irradiation thus explaining the increased risk of rectal bleeding.  
Otherwise established risk factors for late rectal toxicity include advanced 
age (114), larger rectal volume (136), diabetes mellitus (113;114;137;138), 
prior abdominal surgery (138), use of androgen deprivation (139;140), 
haemorrhoids (111;141) or inflammatory bowel disease (142). Furthermore 
acute rectal toxicity is associated with an increased risk of late rectal 
toxicity (143;144). The latter raises the interesting question to whether early 
intervention to lessen acute toxicity might also reduce the risk of late 
toxicity.  
Limitations in these studies are as mentioned before a small number of both 
patients and events, this limits the statistical power. The very low toxicity 
rates found combined with the relatively small number of patients in the 
studies and the non-negligible competing risks of death and biochemical 
failure, may have led to an underestimation of the toxicity frequencies 
found. Baseline assessments before RT would be preferable to better 
evaluate both toxicity and QoL. This may be particularly relevant in an 
elderly patient population like prostate cancer patients as some symptoms 
may be due to undetected co-morbidity progression. Age-matched control 
groups are known to be affected by significant urinary problems (145). 
A delicate balance exists aiming for both maximum accuracy (high BFFS) 
and maximum margin reduction (low toxicity).  The exact incidence and 
extent of microscopic disease remains uncertain because of limits in 
imaging modalities. A study from Heemsbergen et al. (146) has reported 
fewer clinical failures for high-risk prostate cancer patients treated with 
rectangular fields, compared to conformal fields underlining the above 
mentioned problem. Recent reports of decrease in BFFS after margin 
reduction have also been published (69;73;147). A relevant question is 
raised: Maybe margins can be too tight, thus compromising clinical failure 
and in the end survival. The extent of microscopic disease remains uncertain 
because of limits in imaging modalities (147). The potential benefit of an 
inaccurate CTV could be that it accounts for errors that we would normally 
consider part of the PTV expansion. Future developments in modern 
imaging technology will hopefully help solving this problem.   
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MRI delineation and MR-CT co-registration is today feasible as part of 
IGRT treatment for prostate cancer. The utilisation of MRI in patient work-
up process is potentially expensive, time consuming and not always 
accessible in all radiotherapy departments. It may be discussed whether the 
differences in toxicity and QoL between the MR and CT group observed in 
these studies are clinically relevant.  The effect of MRI delineation will 
require further confirmation with future prospective studies on more 
patients and longer follow-up time to evaluate the clinical relevance in term 
of possible toxicity reduction and gain in QoL.  
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CHAPTER 9. CONCLUSIONS 
Four papers are included in this ph.d thesis. The main conclusions are 
summarized below. 
• MRI delineation and MR-CT co-registration is feasible as part of IGRT 
treatment for prostate cancer. 
• MR delineation is followed by a significant reduction in CVT compared to 
CT delineation – also in a clinical setting. 
• Significantly lower rectal high doses and mean doses were found after MR 
delineation. 
• CTV was found to be the most consistent risk factor for rectal bleeding 
after PCa RT 
• Toxicity levels after modern RT of prostate cancer are very low both using 
standard CT delineation and MRI delineation 
• Urinary toxicities are the most frequent toxicities after prostate RT. 
• No difference in overall rectal or urinary toxicity after 3 or 5 years was 
found after MRI or CT delineation 
• No difference in EORTC global health score was registered after MRI or 
CT delineation. 
• Significantly lower EORTC bowel score was found in the MR group. 
• The EORTC bowel score was correlated to CTC-AE overall rectal toxicity 
and v72Gy. 
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Ongoing studies: 
 
Baseline assessment of QoL in a cohort of Danish men undergoing radical 
RT. 
 
Acute toxicity in men undergoing high dose IGRT for PCa after MRI target 
planning and with the use of a prostate stent as fiducial marker. 
 
Prospective toxicity follow-up at baseline, 1, 3 and 5 years after 
radiotherapy using MRI target delineation and IGRT. 
 
Prospective changes in QoL during modern high dose RT. 
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Spørgsmål vedrørende din vandladning. Udfyld venligst skemaet ved at sætte ring om tallet 
ved det udsagn, som bedst besvarer spørgsmålet.  
Aldrig Mindre 
end 1 ud 
af 5 gange 
Mindre 
end 
halvdelen 
af gangene 
Ca. 
halvdelen 
af gangene 
Mere end 
halvdelen af 
gangene 
Næsten 
altid 
1. Hvor mange gange har du
gennem den sidste måned, haft 
fornemmelsen af, at blæren ikke 
blev tømt ordentligt efter endt 
vandladning? 
0 1 2 3 4 5 
2. Hvor mange gange har du
gennem den sidste måned, 
måttet lade vandet med mindre 
end 2 timers mellemrum? 
0 1 2 3 4 5 
3. Hvor mange gange har du
gennem den sidste måned 
oplevet, at vandladningen 
foregår afbrudt over flere 
omgange?  
0 1 2 3 4 5 
4. Hvor mange gange har du
gennem den sidste måned følt 
en bydende stærk vandladnings 
trang som gjorde, at De straks 
måtte lade vandet? 
0 1 2 3 4 5 
5. Hvor mange gange har du
gennem den sidste måned 
oplevet en svag strålekraft? 
0 1 2 3 4 5 
6. Hvor mange gange har du
gennem den sidste måned 
måttet presse for at 
vandladningen kunne komme 
igang? 
0 1 2 3 4 5 
Ingen 1 gang 2 gange 3 gange 4 gange 5 gange eller flere 
7. Hvor mange gange har du
gennem den sidste måned 
gennemsnitlig måttet stå op om 
natten for at lade vandet? 
0 1 2 3 4 5 
Total IPSS score 
Livskvalitet passende til urinvejssymptomer 
Henrykt Tilfreds Over-
vejende 
tilfreds 
Blandet 
tilfreds/ 
utilfreds 
Overvejende 
utilfreds 
Ulykkelig Desperat 
1. Hvis du skulle leve resten af 
livet med din vandladning som 
den foregår nu, ville du så være 
0 1 2 3 4 5 6 
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A significant increase in the prostate cancer incidence has made prostate 
cancer a major health problem in recent years. Because of the often but un-
fortunately not always indolent nature of the disease, over-diagnosis and 
over-treatment are relevant clinical and ethic dilemmas.
External beam radiotherapy is a well established treatment modality for pros-
tate cancer. Accuracy and precision are key words with regard to optimal 
survival and minimal toxicity in modern radiotherapy and are fundamentals 
in modern radiotherapy.
Modern imaging has improved the ability to define radiotherapy target vol-
umes. Especially treatment margins have been reduced through the use of 
more accurate treatment planning and image-guided technology. 
Increasing doses have lead to increased disease control. Aiming for minimal 
toxicity after radiotherapy, magnetic resonance imaging delineation could be 
a possible tool, knowing that clinical target volumes are up to 30% smaller 
on MRI delineation compared to computer tomography delineation. 
The overall aim of the thesis was to explore the use of MRI target plan-
ning and a Nicle-Titanium prostate stent as fiducial marker for both MR-CT 
co-registration and image guided radiotherapy.
